| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
sBLA Submission example | ZYNLONTA (loncastuximab tesirine-lpyl) in combination with rituximab (LOTIS-5) 2L+ diffuse large B-cell lymphoma (DLBCL) Accelerated | sBLA | — | Subscribe to access the data. | Antibody-Drug Conjugates (ADCs) | Oncology | |
sBLA Submission example | ZYNLONTA (loncastuximab tesirine-lpyl) in combination with rituximab (LOTIS-5) 2L+ diffuse large B-cell lymphoma (DLBCL) Accelerated | sBLA | — | Subscribe to access the data. | Antibody-Drug Conjugates (ADCs) | Oncology | |
sBLA Submission example | ZYNLONTA (loncastuximab tesirine-lpyl) in combination with rituximab (LOTIS-5) 2L+ diffuse large B-cell lymphoma (DLBCL) Accelerated | sBLA | — | Subscribe to access the data. | Antibody-Drug Conjugates (ADCs) | Oncology |
Recent Updates
Recently added Catalysts
ADC Therapeutics SA$1.29
-0.01 (-0.77%)
C 51Pipeline Score Undervalued Pharma · Commercial
Market Cap
403.20 M
EPS
-1.05
P/E Ratio
-3.01 $
Value Trade
4.45 M
SEC Financials
Q1 2026Dilution Risk
25%Revenue
20.85 M
R&D Expenses
19.88 M
Operating CF
-29.71 M
Total Assets
291.50 M
Total Liabilities
507.87 M
Equity
-216.38 M
D/E Ratio
12,345
1.8 %
Week
-17.11 %
1 Month
-18.9 %
3 Month
-14.39 %
6 Month
-83.86 %
5 Year
-88.7 %
All Time
Cash Data
Cash Position
231.01 M
Monthly Burn
9.90 M
Runway
21.3 mo
Burn Trend
SEC Filing
May 4, 2026
Overview
Volume
1.33 M
52 Week Range
2.55 - 4.98
% held by Insiders
23.54 %
% held by Institutions
57.67 %
Enterprise Value
288.86 M
Total Shares
123.86 M
Short %
6.17 %
Float Shares
91.04 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for ADC Therapeutics SA
574Total events
9Upcoming
134Tier-1 (high impact)
2018 – 2028Coverage
Upcoming catalysts 9
Event history 565
Jun 30, 2026
▲Enrollment CompleteZYNLONTAApprovedTrial
Enrollment completed in LOTIS-7 Phase 1b trial of ZYNLONTA plus glofitamab
relapsed or refractory diffuse large B-cell lymphomasource ↗
Jun 3, 2026
▲Topline ReadoutZYNLONTAApprovedClinical Data
Topline data from LOTIS-5 confirmatory trial of ZYNLONTA plus rituximab
relapsed or refractory diffuse large B-cell lymphomasource ↗
Jun 3, 2026
▲Primary Endpoint MetZYNLONTAApprovedClinical Data
PFS primary endpoint met with statistical significance
relapsed or refractory diffuse large B-cell lymphomasource ↗
Q2 2026
◆Topline ReadoutZYNLONTAApprovedClinical Data
LOTIS-5 topline results expected in Q2 2026
relapsed or refractory diffuse large B-cell lymphoma (DLBCL)source ↗
Q2 2026
◆Timing GuidancePresentation
Cash runway expected to fund multiple catalysts into second half of 2026
Mar 31, 2026
▲First Patient DosedADCX-020Trial
First patient dosed in Phase 1 trial of ADCX-020
advanced solid tumorssource ↗
Drug Pipeline Intelligence
C51
Pipeline Score $391M
Pipeline ValueUndervalued
Valuation Signal6
Drugs Scored3.2x
rNPV / MCap Top 78%
Micro Cap (rank 201 of 911)
Percentile RankADC Therapeutics SA carries a moderate pipeline score (51/100), with $1.1B risk-adjusted pipeline value, led by Loncastuximab Tesirine in Double-Expressor Lymphoma (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Loncastuximab Tesirine Small molecule | Relapsed Diffuse Large B-Cell Lymphoma | Phase 3 | NCT04384484 | 46% | $532M | ACTIVE NOT_RECRUITING | 440 | SLOW | B (66) | Jun 30, 2028 | MODERATE_RISK | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
ZYNLONTA Accelerated | relapsed or refractory DLBCL | Phase 1b | 2026-06-30 | overall response rate: 89.8%; complete response: 77.6% | ADC Therapeutics Announces Completion of Enrollment in LOTIS-7 Phase 1b ZYNLONTA® Combination Trial Read More | |
ZYNLONTA Accelerated | relapsed or refractory DLBCL | Phase 1b | 2026-06-30 | overall response rate: 89.8%; complete response: 77.6% | ADC Therapeutics Announces Completion of Enrollment in LOTIS-7 Phase 1b ZYNLONTA® Combination Trial Read More | |
ZYNLONTA Accelerated | relapsed or refractory DLBCL | Phase 1b | 2026-06-30 | overall response rate: 89.8%; complete response: 77.6% | ADC Therapeutics Announces Completion of Enrollment in LOTIS-7 Phase 1b ZYNLONTA® Combination Trial Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ADCT
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
ADCT Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
ADCTADC Therapeutics Announces Completion of Enrollment in LOTIS-7 Phase 1b ZYNLONTA® Combination Trial
ADC Therapeutics has completed enrollment in the LOTIS-7 Phase 1b trial, evaluating ZYNLONTA in combination with glofitamab for relapsed or refractory DLBCL. The trial included 100 patients, with results expected in late 2026. Preliminary data shows a high overall response rate, indicating strong potential for this treatment combination.
Read more →ADCT▼ -7%on this news
ADC Therapeutics Announces Strategic Reorganization to Support ZYNLONTA® Growth Opportunities and Regulatory Priorities
ADC Therapeutics has announced a strategic reorganization to support its ZYNLONTA franchise, which includes a planned 17% workforce reduction aimed at generating annual savings of around $10 million. The company is focused on key regulatory milestones, including a pre-sBLA meeting with the FDA and the completion of ongoing clinical trials. This restructuring is intended to enhance financial flexibility while maintaining support for ZYNLONTA's commercial activities.
Read more →ADCTADC Therapeutics Announces Results From LOTIS-5 Phase 3 Confirmatory Clinical Trial of ZYNLONTA® in Combination with Rituximab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
ADC Therapeutics announced positive topline results from the LOTIS-5 Phase 3 trial of ZYNLONTA in combination with rituximab for relapsed or refractory diffuse large B-cell lymphoma. The trial met its primary endpoint of progression-free survival with statistical significance, while also showing improved complete response rates. However, the test arm exhibited higher rates of serious adverse events, particularly in older patients. The company plans to discuss these results with the FDA in preparation for a supplemental Biologics License Application.
Read more →ADCTADC Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Updates
ADC Therapeutics reported a net product revenue of $20 million for Q1 2026, reflecting growth from the previous year. The company anticipates topline results from the LOTIS-5 Phase 3 trial in Q2 2026 and full data by year-end. Despite a significant net loss of $33 million, ADC maintains a robust cash position, projecting a runway into 2028.
Read more →ADCTADC Therapeutics Makes Grants to New Employees Under Inducement Plan ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that...
ADC Therapeutics announced the grant of stock options to two new employees as an inducement for their employment, totaling 49,400 shares. This decision was approved by the company’s Compensation Committee to motivate and reward performance under its Inducement Plan. By offering these grants, ADC Therapeutics aims to enhance its workforce capabilities and contribute to the company's overall success.
Read more →ADCTADC Therapeutics to Host First Quarter 2026 Financial Results Conference Call on May 4, 2026
ADC Therapeutics announced a conference call scheduled for May 4, 2026, to discuss its first quarter financial results and operational updates. The call will be accessible via a toll-free number and a live webcast. The company is recognized for its advancements in antibody drug conjugates, particularly with ZYNLONTA, which has received FDA approval.
Read more →ADCTADC Therapeutics S.A. Investigated by the Portnoy Law Firm
ADC Therapeutics S.A. is under investigation by the Portnoy Law Firm for potential securities fraud related to its recent stock drop. This decline was precipitated by safety concerns regarding its oncology therapeutic development program. A significant decrease in stock price was linked to new data from the LOTIS-7 Phase 1b trial, where safety signals raised alarms about combination treatment risks. The firm is encouraging affected investors to discuss their legal options.
Read more →ADCTADC Therapeutics Announces New Employee Inducement Grant
ADC Therapeutics announced a grant of options to purchase 17,000 common shares to a new employee as an inducement for employment. This grant, approved by the Compensation Committee, is designed to motivate the employee and align their interests with the company's success. The options will vest over four years, encouraging long-term commitment.
Read more →ADCTADC Contract Manufacturing Market Report 2026 (7th Edition) | Commercial Scale Dominates ADC Manufacturing with 90% Market Share | A Clear Analysis of Market Trends, Drivers, Challenges, and Opportunities
The ADC contract manufacturing market is projected to expand significantly, increasing from USD 2.13 billion to USD 3.21 billion by 2035, with a CAGR of 4.6%. The growing role of antibody drug conjugates (ADCs) in cancer treatments drives this expansion, particularly as many developers are outsourcing to contract manufacturers. The market is primarily dominated by the commercial scale, accounting for nearly 90% of the sector. North America is anticipated to see substantial growth, while Asia-Pacific regions also exhibit promising growth rates due to cost advantages.
Read more →ADCTAdcytherix Doses First Patient in Phase 1 Trial of ADCX-020 and Strengthens Leadership to Support Next Phase of Growth
Adcytherix announced the dosing of its first patient in a Phase 1 clinical trial of ADCX-020, marking its transition to a clinical-stage company. The trial aims to assess the safety and anti-tumor activity of ADCX-020 in patients with advanced solid tumors. Additionally, the company has reinforced its leadership team with significant appointments to support pipeline expansion and growth strategies. The successful dosing comes less than two years after the company's inception and follows a substantial financing round.
Read more →ADCT▲ +13.5%on this news
ADC Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Operational Update ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today reported...
ADC Therapeutics reported its fourth quarter and full year 2025 financial results, highlighting a net product revenue of approximately $73.6 million for the year. The company anticipates significant milestones in 2026 with topline data expected from the LOTIS-5 Phase 3 trial. Despite a net loss for the year, ADC has a strong cash position projected to support operations until at least 2028, allowing for continued investment in its ZYNLONTA clinical programs. A strategic amendment to its financing agreement was also noted, which may enhance future operational flexibility.
Read more →ADCTADC Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call on March 10, 2026
ADC Therapeutics will host a conference call on March 10, 2026, to discuss its financial results for Q4 and the full year of 2025. The call will provide operational updates and is accessible via a toll-free number and a live webcast. ADC Therapeutics continues to innovate in the field of antibody drug conjugates, particularly with its product ZYNLONTA.
Read more →ADCTADC Cytotoxic Payloads and Warheads Industry Research Report 2026-2035 - Breakthrough Cancer Therapies and Next-Generation ADC Innovations Accelerate Market Expansion
The ADC cytotoxic payloads and warheads market is projected to grow significantly, reaching USD 720.2 million by 2035 from USD 469.3 million today, driven by advancements in targeted cancer therapies. Innovations in linker and payload technologies are optimizing therapeutic efficacy, while increased investment supports market expansion. However, challenges such as the complexity of handling potent substances and high development costs may impede progress. Notably, Europe is expected to lead the market, thanks to strong collaborations and advanced manufacturing capabilities.
Read more →ADCTADC Therapeutics Makes Grants to New Employees Under Inducement Plan
ADC Therapeutics has granted options to purchase 135,000 shares to three new employees as part of its Inducement Plan. This initiative aims to motivate and reward the new hires, ensuring their contributions to the company's success. The grants will vest over four years, contingent on continued employment.
Read more →ADCTADC Therapeutics to Participate in March Investor Conferences
ADC Therapeutics announced its participation in two upcoming investor conferences in March 2026. The events include the TD Cowen 46th Annual Health Care Conference and the Jefferies Biotech on the Beach Summit. CEO Ameet Mallik will present at the TD Cowen conference, highlighting the company's advancements in antibody drug conjugates, particularly ZYNLONTA.
Read more →ADCT▲ +7.6%on this newsshared move
ADC Therapeutics Announces Amended HealthCare Royalty Financing Agreement
ADC Therapeutics has amended its royalty purchase agreement with HealthCare Royalty, reducing the change of control payment significantly. This change reflects confidence in the long-term potential of ZYNLONTA, which is expected to generate substantial revenue. The new terms also grant HealthCare Royalty warrants for common shares, enhancing the partnership's strategic flexibility.
Read more →ADCTADC Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Revenue and Cash Estimates and Recent Corporate Updates
ADC Therapeutics reported preliminary unaudited revenue estimates for Q4 and full year 2025, projecting approximately $22 million and $73 million, respectively. The company also highlighted a cash position of $261 million, ensuring a runway until at least 2028. Key upcoming milestones include the completion of LOTIS-7 enrollment and topline data from LOTIS-5, both expected in 2026.
Read more →ADCTADC Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that...
ADC Therapeutics announced that CEO Ameet Mallik will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on January 15, 2026. The company is recognized as a pioneer in antibody drug conjugates and has made significant advancements with its product ZYNLONTA, which has received FDA approval. A live webcast of the presentation will be accessible on the company's website. The firm continues to develop other promising therapies, including a next-generation ADC targeting PSMA.
Read more →ADCTADC Therapeutics Announces New Employee Inducement Grant - January 2, 2026
ADC Therapeutics has announced a grant of options to purchase 6,000 common shares to a new employee as an inducement for employment. This grant, approved by the Compensation Committee, is part of the company's strategy to motivate and reward high performance. The options will vest over four years, contingent on continued employment.
Read more →ADCTCorporate Presentation January 2026 2 Forward - Looking Statements This presentation and any accompanying oral presentation have been prepared by ADC Therapeutics SA ("ADC Therapeutics", "we" or "us") for informational p
ADC Therapeutics has released its corporate presentation detailing its growth strategy and forward-looking statements. The company emphasizes its pioneering role in the field of antibody-drug conjugates (ADCs) and outlines the commercial potential of its FDA-approved treatment, ZYNLONTA. With a projected cash runway extending to 2028, ADC Therapeutics is focusing on refining its clinical trials and addressing various regulatory and market factors. The presentation highlights methodical portfolio management, though it also acknowledges the inherent uncertainties in forward-looking statements regarding its performance and financial health.
Read more →ADCT▼ -14.1%on this news· ran to -30% by day 3
ADC Therapeutics Announces Updated Data from LOTIS-7 Phase 1b Clinical Trial of ZYNLONTA® in Combination with Bispecific Antibody Supporting Potential Best-in-Class Regimen in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma
ADC Therapeutics announced promising updated data from the LOTIS-7 Phase 1b trial, showing ZYNLONTA combined with glofitamab achieved an 89.8% overall response rate and 77.6% complete response rate in patients with relapsed/refractory diffuse large B-cell lymphoma. The combination therapy is well-tolerated, and the trial is on track for complete enrollment by mid-2026, with full data expected to be shared at a medical meeting and submitted for publication by the end of 2026.
Read more →ADCT▼ -14.1%on this news· ran to -30% by day 3shared move
ADC Therapeutics to Provide Update on LOTIS-7 Clinical Trial
ADC Therapeutics announced a corporate webcast scheduled for December 3, 2025, to provide an update on the LOTIS-7 Phase 1b clinical trial. This trial evaluates the safety and efficacy of ZYNLONTA in combination with glofitamab for patients with relapsed or refractory diffuse large B-cell lymphoma. The webcast will be accessible to the public, highlighting the company's commitment to transparency.
Read more →ADCTAdcytherix Powers Ahead: Technology and Team in Place to Deliver Strategy and Build an ADC Powerhouse
Adcytherix has made significant strides in bolstering its capabilities by operationalizing the ADCX - Engine and enhancing its executive team with the appointments of a new CMO and CFO. The ADCX - Engine is designed to produce innovative antibody-drug conjugates aimed at treating hard-to-treat cancers. The company is positioned for accelerated growth following a successful €105 million Series A financing, aiming to transition from early-stage development to clinical execution within the biopharmaceutical landscape.
Read more →ADCTADC Therapeutics Reports Third Quarter 2025 Financial Results and Provides Operational Update
ADC Therapeutics reported its third quarter 2025 financial results, highlighting progress in clinical trials for ZYNLONTA and a strengthened balance sheet following recent financing. The company anticipates multiple data readouts from ongoing trials in 2026, including LOTIS-7 and LOTIS-5. Despite a reported net loss, the outlook for ZYNLONTA's expansion into earlier treatment lines appears optimistic.
Read more →ADCT▼ -6.3%on this news
ADC Therapeutics to Host Third Quarter 2025 Financial Results Conference Call on November 10, 2025
ADC Therapeutics announced a conference call scheduled for November 10, 2025, to discuss its third quarter financial results and operational updates. The call will be accessible via a toll-free number and a live webcast. The company continues to innovate in the field of antibody drug conjugates, particularly with its product ZYNLONTA.
Read more →ADCTADC Therapeutics to Present at November Investor Conferences
ADC Therapeutics announced its participation in three investor conferences scheduled for November 2025. CEO Ameet Mallik will present at each event, including the Stephens Biotechnology Virtual Fireside Chats and the Guggenheim Healthcare Innovation Conference. The company continues to advance its portfolio, particularly with ZYNLONTA, which has received regulatory approvals.
Read more →ADCTAdcytherix Raises EUR 105M Series A to Accelerate Breakthrough Antibody-Drug Conjugate Pipeline with Strategic Focus on Novel Payloads
Adcytherix SAS has announced the successful closure of a EUR 105 million Series A funding round, aimed at boosting its antibody-drug conjugate (ADC) pipeline. Led by Bpifrance and involving prominent investors such as Kurma Partners and Surveyor Capital, this investment positions Adcytherix for significant growth. The financing will primarily advance its lead candidate ADCX-020 into clinical evaluation, with both IND and CTA submissions expected by the end of 2025. The company is focused on developing innovative ADCs using novel payloads to address cancer therapies.
Read more →ADCTADC Therapeutics Announces $60 Million Private Placement
ADC Therapeutics has announced a $60 million private placement to institutional investors, selling 11.3 million common shares at $4.00 each. The funds will be used to support the commercial expansion of ZYNLONTA and strengthen the company's balance sheet. The financing is expected to close on October 27, 2025, and will enhance the company's cash runway into 2028.
Read more →ADCTCorporate Presentation October 2025 Forward - Looking Statements This presentation and any accompanying oral presentation have been prepared by ADC Therapeutics SA ("ADC Therapeutics", "we" or "us") for informational pur
ADC Therapeutics SA presented forward-looking statements regarding their strategies and performance in the ADC market during their October 2025 corporate presentation. Key highlights include the expansion plans for their FDA-approved drug ZYNLONTA and the progress of their PSMA-targeting ADC candidate. The company assures stakeholders of its capability and robust cash runway expected into 2028, although risks related to clinical trial outcomes and regulatory approvals were also noted. Users were encouraged to refer to ZYNLONTA's prescribing information for comprehensive details about the drug.
Read more →ADCTADC Innovator Myricx Bio Appoints Boston-based Mohit Rawat as CEO and Expands Team in US and UK
Myricx Bio has appointed Mohit Rawat as the new CEO, transitioning from his previous role as President at Fusion Pharmaceuticals. The company is expanding its team in the US and UK to support the upcoming clinical development of its lead NMTi-ADC candidate, funded by a recent £90 million Series A financing. The NMTi-ADC platform aims to improve tolerability and overcome payload resistance in cancer treatments. The leadership change reflects Myricx's ambition to enhance its position in the ADC therapeutics market.
Read more →ADCTADC Therapeutics to Present at the Cantor Global Healthcare Conference 2025
ADC Therapeutics will present at the Cantor Global Healthcare Conference 2025, with CEO Ameet Mallik participating in a fireside chat. The event is scheduled for September 3, 2025. The company is recognized for its innovative work in antibody drug conjugates, particularly with its product ZYNLONTA, which has received FDA approval.
Read more →ADCT▲ +9.7%on this news
ADC Therapeutics Reports Second Quarter 2025 Financial Results and Provides Operational Update ZYNLONTA® in combination with glofitamab (COLUMVI®) demonstrated overall response rate (ORR) of 93.3% and a complete response (CR) rate of 86.7% in...
ADC Therapeutics reported strong second quarter financial results for 2025, highlighting the successful performance of ZYNLONTA in combination with glofitamab. The overall response rate for this combination treatment reached an impressive 93.3%, with a complete response rate of 86.7%. The company is actively expanding its trials, including the LOTIS-7 study, and has secured a $100 million private placement to strengthen its financial position until 2028. Key clinical milestones are expected in the coming years, showcasing ADC's commitment to advancing its therapeutic opportunities.
Read more →ADCTADC Therapeutics to Host Second Quarter 2025 Financial Results Conference Call on August 12, 2025 ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that...
ADC Therapeutics SA (NYSE: ADCT) has announced a conference call scheduled for August 12, 2025, to discuss its financial results for the second quarter of 2025. The call reflects the company’s commitment to keeping shareholders informed and engaged. ADC Therapeutics continues to advance its portfolio, notably with the FDA-approved ZYNLONTA for treating lymphoma and ongoing developments in its PSMA-targeting ADC. However, the company has also acknowledged risks related to future clinical and regulatory processes that may affect their operational outcomes.
Read more →ADCTADC Therapeutics Makes Grant to New Employee Under Inducement Plan ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that...
ADC Therapeutics SA (NYSE: ADCT) has announced the grant of 17,000 options for common shares to a new employee as part of its Inducement Plan. This initiative aims to motivate and reward the employee to drive significant contributions to the company. Grants will vest over four years, contingent on continued employment. ADC Therapeutics is known for its pioneering work in antibody drug conjugates and has ongoing developments in its product lines.
Read more →ADCT▼ -5.6%on this news· ran to -23% by day 3
ADC Therapeutics Announces Updated ZYNLONTA® Investigator-Initiated Trial Data in R/R Marginal Zone Lymphoma Presented at 18th International Conference on Malignant Lymphoma (ICML) ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced...
ADC Therapeutics has presented updated Phase 2 trial data for ZYNLONTA, showing an overall response rate of 85% in patients with relapsed/refractory marginal zone lymphoma (r/r MZL). The complete response rate reached 69%, and the longest duration of complete response observed was 27 months. The trial, conducted at multiple sites, included 27 enrolled patients, with a focus on expanding to additional sites to reach 50 participants. The results support ZYNLONTA's potential as a single-agent therapy, prompting possible regulatory pathways if positive trends continue.
Read more →ADCTADC Therapeutics Announces $100 Million Private Placement Extending Expected Cash Runway into 2028 ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that...
ADC Therapeutics has entered into a $100 million private investment in public equity (PIPE), selling common shares to institutional investors. The financing aims to support its clinical development of ZYNLONTA and other initiatives. However, the company will also stop early development on certain programs and reduce its workforce by about 30%. Despite these challenges, the PIPE financing is expected to extend the company's cash runway into 2028, facilitating future growth.
Read more →ADCTADC Therapeutics Announces Updated Data from LOTIS-7 Clinical Trial Presented at the European Hematology Association 2025 Congress ZYNLONTA® in combination with glofitamab (COLUMVI®) in patients with r/r DLBCL demonstrated clinically meaningful benefit with overall response rate...
ADC Therapeutics announced promising results from the LOTIS-7 clinical trial for ZYNLONTA combined with glofitamab in treating relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). The study revealed a high overall response rate of 93.3% and an impressive complete response rate of 86.7%. These findings support further expansion of the trial, increasing enrollment to 100 patients at a higher dose. The safety profile of the combination therapy appears manageable with favorable efficacy data.
Read more →ADCT▼ -6.6%on this news· ran to +19% by day 3
ADC Therapeutics to Present at Upcoming Investor Conferences ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced...
ADC Therapeutics SA (NYSE: ADCT) will present at two upcoming investor conferences: the RBC Capital Markets Global Healthcare Conference on May 21, 2025, and the Jefferies Global Healthcare Conference on June 5, 2025. CEO Ameet Mallik will lead discussions in fireside chat formats for both events. The presentations will be available via webcast, and ADC Therapeutics continues to advance its antibody drug conjugate technologies. The company has received accelerated approval from the FDA for its CD19-directed ADC, ZYNLONTA.
Read more →ADCT▲ +37.1%on this news· ran to +77% by day 3shared move
ADC Therapeutics Reports First Quarter 2025 Financial Results and Provides Operational Update LOTIS-7 abstract accepted for presentation at the European Hematology Association 2025 Congress (EHA2025) and the 18th International Conference on...
ADC Therapeutics reported its first quarter 2025 financial results and highlighted operational updates, including acceptance of the LOTIS-7 abstract for presentation at major conferences. The company noted positive outcomes from the LOTIS-7 trial, where ZYNLONTA combined with glofitamab achieved a high overall response rate. They also reported a sufficient cash runway to support upcoming initiatives through mid-2026. The CEO expressed confidence in the potential of ZYNLONTA as they aim for broader therapeutic opportunities.
Read more →ADCT▲ +37.1%on this news· ran to +77% by day 3shared move
ADC Therapeutics Announces Presentation of LOTIS-7 Clinical Trial Data at the European Hematology Association 2025 Congress (EHA2025) and the 18th International Conference on Malignant Lymphoma (ICML) ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced data...
ADC Therapeutics has announced the presentation of promising data from the LOTIS-7 Phase 1b clinical trial during upcoming conferences in 2025. The trial evaluated the efficacy of ZYNLONTA in combination with glofitamab for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Key findings include an impressive 95.5% overall response rate and a 90.9% complete response rate. The data will be presented at the European Hematology Association 2025 Congress and the International Conference on Malignant Lymphoma.
Read more →ADCTADC Therapeutics to Host First Quarter 2025 Financial Results Conference Call on May 14, 2025 ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that...
ADC Therapeutics announced a conference call scheduled for May 14, 2025, to discuss its financial results for the first quarter of 2025 as well as provide updates on its operations. The company is recognized as a leader in antibody drug conjugates, specifically with its ADC ZYNLONTA. This call will be significant for investors as it may outline revenue expectations and developmental progress. However, the company also faces inherent risks related to revenue generation and financial obligations.
Read more →ADCT▲ +9.8%on this news
ADC Therapeutics Announces Preclinical Data Highlighted at the American Association for Cancer Research Annual Meeting 2025 ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced data...
ADC Therapeutics reported positive preclinical data on its novel antibody drug conjugates at the AACR Annual Meeting 2025. Key highlights included the presentation of ADCT-242, which targets Claudin-6 and showed significant antitumor effects in ovarian and non-small lung cancer models. Additionally, the company showcased its PSMA-targeting and ASCT2-targeting ADCs, which demonstrated promising antitumor activity and safety. This evidence positions ADCT as a leader in advancing ADC technology for various cancer treatments.
Read more →ADCTADC Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference ADC Therapeutics SA (NYSE: ADCT) announced today that Ameet Mallik, Chief Executive Officer, will present a company overview at the 24th Annual...
ADC Therapeutics announced that CEO Ameet Mallik will present an overview at the 24th Annual Needham Virtual Healthcare Conference on April 8, 2025. The conference will be accessible via a live webcast, with a replay available for 30 days. ADC Therapeutics is noted for its advancements in antibody drug conjugates, particularly with its FDA-approved treatment ZYNLONTA for certain lymphomas. The company continues to work on expanding its ADC technology across various cancers.
Read more →ADCTADC Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Operational Update Initial data from LOTIS-7 Phase 1b trial of ZYNLONTA® plus glofitamab demonstrated clinically meaningful benefit with 94% best ORR and 72% CR rate;...
ADC Therapeutics reported its financial results for Q4 and the full year 2024, highlighting significant achievements including the completion of enrollment in the LOTIS-5 Phase 3 trial and promising data from the LOTIS-7 trial. The initial findings from the LOTIS-7 trial indicate a favorable overall response rate of 94% and a complete response rate of 72%. The company also noted a solid cash position, expected to support operations into the second half of 2026. Upcoming data updates and pivotal milestones are anticipated in 2025, maintaining a positive outlook for the company.
Read more →ADCTADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2025 ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced...
ADC Therapeutics has announced that multiple abstracts detailing their preclinical programs have been accepted for presentation at the American Association for Cancer Research Annual Meeting 2025. The company will showcase data on its Claudin-6, PSMA, and ASCT2-targeted antibody-drug conjugates, highlighting their potential for treating various cancer types. The presentations are scheduled for specific dates during the event in Chicago from April 25-30, 2025. The findings could contribute significantly to advancements in targeted cancer therapies.
Read more →ADCT▼ -6.6%on this newsshared move
ADC Therapeutics to Host Fourth Quarter and Year-End 2024 Financial Results Conference Call on March 27, 2025 ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that...
ADC Therapeutics will hold a conference call on March 27, 2025, to discuss its financial results for Q4 and the full year of 2024. The company aims to provide operational updates, showcasing its advancements in antibody drug conjugates technology. Their flagship product, ZYNLONTA, has received accelerated approval for certain types of lymphomas and is being explored in various clinical settings. However, the company acknowledges the risks associated with future projections and operational challenges in the market.
Read more →ADCTADC Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that...
ADC Therapeutics has announced that CEO Ameet Mallik will participate in a fireside chat at the Guggenheim SMID Cap Biotech Conference on February 6, 2025. The event will provide opportunities for showcasing the company's advancements in antibody drug conjugates, including ZYNLONTA, its FDA-accelerated drug for certain lymphomas. A live webcast of the chat will be accessible on the ADC Therapeutics website, complementing their ongoing efforts in clinical and preclinical ADC development.
Read more →ADCT▼ -8.5%on this news
JPMorgan 43 rd Annual Healthcare Conference January 2025 2 Forward - Looking Statements This presentation and any accompanying oral presentation have been prepared by ADC Therapeutics SA ("ADC Therapeutics", "we" or "us"
ADC Therapeutics presented at the JPMorgan 43rd Annual Healthcare Conference in January 2025, discussing forward-looking statements about its operations. The company aims to expand its commercialized drug ZYNLONTA while developing an early-stage solid tumor portfolio. It highlighted potential revenue growth and cash runway into mid-2026 but acknowledged risks related to regulatory approvals and product commercialization. Additionally, the discontinuation of certain programs may affect future outcomes.
Read more →ADCT▼ -6.4%on this newsshared move
ADC Therapeutics Announces Completion of Enrollment of Phase 3 Confirmatory Clinical Trial of ZYNLONTA® in Combination with Rituximab in 2L+ Diffuse Large B-Cell Lymphoma ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced the...
ADC Therapeutics has announced the completion of enrollment for its Phase 3 confirmatory clinical trial, LOTIS-5, which evaluates the efficacy of ZYNLONTA in combination with rituximab for patients with relapsed or refractory diffuse large B-cell lymphoma. The trial aims to confirm previous accelerated approval and could provide a new treatment option in the second-line setting. Topline results are expected by the end of 2025, with potential FDA submission in early 2026, indicating anticipated growth in the therapy's market presence.
Read more →ADCT▼ -36.2%on this news
ADC Therapeutics Announces Positive Initial Data from LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Bispecific Antibody in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced...
ADC Therapeutics announced positive initial data from the Phase 1b LOTIS-7 trial evaluating ZYNLONTA in combination with glofitamab for patients with relapsed or refractory diffuse large B-cell lymphoma. The study found a 94% overall response rate and reported no severe toxicities, which bodes well for the treatment's safety profile. The company anticipates completing patient enrollment in the trial by mid-2025 and plans to engage regulatory authorities moving forward. Initial findings could position this combination as a leading option in a competitive market.
Read more →ADCTADC Therapeutics Announces The Lancet Haematology Publication of Data from Investigator-Initiated Trial Evaluating ZYNLONTA® in Combination with Rituximab to Treat Relapsed/Refractory Follicular Lymphoma ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced...
ADC Therapeutics announced the publication of positive data in The Lancet Haematology from a Phase 2 trial of ZYNLONTA combined with rituximab for treating relapsed or refractory follicular lymphoma. The trial demonstrated a high overall response rate of 97% and a complete response rate of 77%, highlighting significant effectiveness in high-risk patients. Additionally, promising results from a separate trial of ZYNLONTA as a monotherapy for marginal zone lymphoma were showcased, further indicating the drug's evolving role in treating B-cell lymphomas.
Read more →ADCT▲ +63%on this newsshared move
ADC Therapeutics to Provide Initial Data Update on LOTIS-7 Clinical Trial ADC Therapeutics SA (NYSE: ADCT), today announced that it will host a conference call and live webcast on Wednesday, December 11, 2024, at 8:30 a.m....
ADC Therapeutics has announced that it will host a conference call to share preliminary data from the LOTIS-7 clinical trial on December 11, 2024. This trial evaluates the combination of ZYNLONTA and glofitamab in patients with relapsed or refractory diffuse large B-cell lymphoma. The company is a leader in antibody drug conjugates and aims to transform the treatment of various malignancies. The trial updates may shed light on the efficacy and safety of this combination therapy.
Read more →ADCTADC Contract Manufacturing Market Industry Trends and Global Forecasts to 2035 - IgG1 Antibody Isotype Segment is Likely to Dominate the ADC Contract Manufacturing Market During the Forecast Period
The ADC contract manufacturing market is forecasted to experience significant growth, climbing from USD 1.79 billion to USD 6.88 billion by 2035, driven by demand for antibody-drug conjugates (ADCs). More than 20 ADC programs have been approved by regulatory authorities, and over 260 therapies are currently in clinical trials. Despite the promising growth, challenges such as manufacturing side reactions and the need for substantial capital investment pose risks. The market demonstrates a trend towards outsourcing manufacturing processes, further accentuating its growth potential.
Read more →ADCT▼ -8.4%on this news
ADC Therapeutics Reports Third Quarter and Year-to-Date 2024 Financial Results and Provides Operational Update ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today reported...
ADC Therapeutics has reported its financial results for the third quarter of 2024, highlighting operational advancements, particularly with its ZYNLONTA treatment for hematological malignancies. The company anticipates full enrollment in the LOTIS-5 trial by year-end and will present updated ZYNLONTA data at the upcoming American Society of Hematology meeting in December. However, the firm is discontinuing its ADCT-601 program to focus on an exatecan-based platform for solid tumors. Overall, ADC Therapeutics remains optimistic about its future growth prospects fueled by a solid cash position.
Read more →ADCTADC Therapeutics Announces Investigator-Initiated Study Abstracts Accepted for Presentation at the 66th ASH Annual Meeting ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced...
ADC Therapeutics announced that independent investigator-initiated study abstracts on ZYNLONTA have been accepted for presentation at the 66th ASH Annual Meeting. These studies include a Phase 2 trial evaluating ZYNLONTA in combination with rituximab for high-risk relapsed or refractory follicular lymphoma, showing a 97.1% overall response rate. Another study reported an 85% overall response rate for ZYNLONTA as a single-agent treatment for relapsed or refractory marginal zone lymphoma. Presentations are scheduled for December 7-10, 2024 in San Diego, California.
Read more →ADCTADC Therapeutics to Present at November Investor Conferences ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced...
ADC Therapeutics SA (NYSE: ADCT) has announced its participation in two upcoming investor conferences in November 2024, featuring CEO Ameet Mallik in presentations at both events. The conferences are the Guggenheim Securities Healthcare Innovation Conference on November 11 and the Jefferies London Healthcare Conference on November 19. Live webcasts of the presentations will be available, and a replay will be accessible for approximately 30 days following each event. ADC Therapeutics is known for its pioneering work in antibody drug conjugates, notably the FDA-approved ZYNLONTA for lymphomas.
Read more →ADCTADC Therapeutics to Host Third Quarter 2024 Financial Results Conference Call on November 7, 2024 ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that...
ADC Therapeutics will host a conference call on November 7, 2024, at 8:30 a.m. EST to discuss its financial results for Q3 2024 and provide operational updates. The call will include the opportunity for participants to access a live webcast. The company continues to advance its ADC technology, focusing on the treatment of hematologic malignancies and solid tumors, with ZYNLONTA receiving accelerated approval for specific treatments. There are ongoing developments and partnerships that may influence future growth.
Read more →ADCTADC Therapeutics gewährt neuen Mitarbeitern Zuteilungen im Rahmen des Anreizplans
ADC Therapeutics has granted stock options to six new employees as part of its incentive plan. This move aims to motivate and reward employees for their contributions to the company's success. The options will vest over a four-year period, encouraging long-term commitment. The announcement aligns with NYSE regulations regarding employment incentives.
Read more →ADCT▼ -5.9%on this news
ADC Therapeutics hält Vorträge auf bevorstehenden Investorenkonferenzen
ADC Therapeutics has announced its participation in two upcoming investor conferences in September 2024. CEO Ameet Mallik will present at both the H.C. Wainwright Annual Global Investment Conference and the Cantor Global Healthcare Conference. Live webcasts of the presentations will be available on the company's website, allowing for broader investor access.
Read more →ADCT▼ -5.9%on this news
ADC Therapeutics to Present at Upcoming Investor Conferences
ADC Therapeutics announced its participation in two upcoming investor conferences in September 2024. The CEO, Ameet Mallik, will present at both events, which include the H.C. Wainwright 26th Annual Global Investment Conference and the 10th Cantor Global Healthcare Conference. Live webcasts of the presentations will be available, enhancing investor engagement.
Read more →ADCT▼ -6.2%on this news
ADC Therapeutics berichtet über Finanzergebnisse des zweiten Quartals 2024 und gibt aktuelle Informationen zum Geschäftsbetrieb bekannt
ADC Therapeutics reported a net revenue of $17 million for ZYNLONTA in Q2 2024, marking commercial profitability. The company is on track with the LOTIS-7 study, expecting efficacy and safety data by the end of 2024 and comprehensive data by mid-2025. Full recruitment for the LOTIS-5 study is anticipated by the end of 2024.
Read more →ADCTADC Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational Update
ADC Therapeutics reported a successful second quarter for 2024, with ZYNLONTA generating $17 million in sales and achieving commercial profitability. The company is on track with its LOTIS-7 trial, expecting efficacy and safety data by the end of 2024. Full enrollment in the LOTIS-5 trial is anticipated before year-end, positioning the company for continued growth.
Read more →ADCTADC Therapeutics to Host Second Quarter 2024 Financial Results Conference Call on August 6, 2024
ADC Therapeutics SA has announced a conference call scheduled for August 6, 2024, where it will share financial results for the second quarter of 2024 and provide operational updates. The company, known for its focus on antibody drug conjugates, has recently received FDA approval for its drug ZYNLONTA. However, it faces several risks, including operational uncertainties and competition in the biotech sector.
Read more →ADCTADC Therapeutics Set to Join Russell 2000 and Russell 3000 Indexes
ADC Therapeutics announced its upcoming inclusion in the Russell 2000® Index and the Russell 3000® Index, effective July 1, 2024. This recognition reflects the company's progress and strategic execution in their operations. CEO Ameet Mallik emphasized that this milestone serves as validation of their capital allocation strategies. The Russell indexes are widely utilized by investors, further increasing ADC Therapeutics' visibility in the market.
Read more →ADCTADC Contract Manufacturing Market, 2035 - Surging Demand for Antibody Drug Conjugates Driving Growth
The ADC contract manufacturing market is set for substantial growth, estimated to reach approximately $6.87 billion by 2035. This growth is largely driven by rising demand for antibody drug conjugates (ADCs) as effective cancer therapeutics. The manufacturing process remains complex and requires advanced expertise, prompting developers to outsource their production needs to contract manufacturers. Notably, North America is home to over 50% of these manufacturers, underscoring its central role in this market.
Read more →ADCT▼ -13.7%on this news
Adcytherix Launches with € 30m in Seed Funding to Develop Next Generation Antibody Drug Conjugates
Adcytherix has launched with €30 million in seed funding to develop next-generation antibody-drug conjugates targeting high unmet need diseases such as cancer. The company, founded by a team with a successful track record, aims to establish itself as a leading developer in the ADC space. The funding round was led by Pontifax and includes several notable life science investors, highlighting strong confidence in the management team and their vision for oncology advancements.
Read more →ADCTADC Therapeutics to Participate in the Jefferies Global Healthcare Conference
ADC Therapeutics (NYSE: ADCT) is set to present at the Jefferies Global Healthcare Conference on June 6, 2024. CEO Ameet Mallik will provide an overview of the company, which specializes in antibody drug conjugates and is advancing treatments for hematologic malignancies and solid tumors. The company’s lead product, ZYNLONTA, has received accelerated approval from the FDA for specific lymphoma treatments and is undergoing further developmental studies. A live webcast will be available during the presentation, with a replay offered for 30 days after the event.
Read more →ADCTADC Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
ADC Therapeutics announced that CEO Ameet Mallik will participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference on May 20, 2024. The presentation will be webcast live, making it accessible to a wider audience. ADC Therapeutics is notable for its advancements in antibody drug conjugates, particularly with its FDA-approved product ZYNLONTA. The company continues to develop additional therapies while maintaining operational activities in various global locations.
Read more →ADCTCorporate Presentation 2Q 2024 2 Forward - Looking Statements This presentation and any accompanying oral presentation have been prepared by ADC Therapeutics SA ("ADC Therapeutics", "we" or "us") for informational purpos
ADC Therapeutics SA presented its corporate strategy and pipeline in a recent presentation. The focus is on both hematology and solid tumors, while cash runway is projected into mid-2026. Key products under discussion include ZYNLONTA and investigational drugs ADCT-601 and ADCT-602, with expected milestones set for the near future. However, the company acknowledges several risks, including uncertainty regarding revenue from clinical trials and reliance on regulatory approvals.
Read more →ADCTADC Therapeutics to Participate in 2024 RBC Capital Markets Global Healthcare Conference
ADC Therapeutics announced that CEO Ameet Mallik will participate in a fireside chat at the 2024 RBC Capital Markets Global Healthcare Conference on May 14, 2024. This event is an opportunity for the company to showcase its developments in antibody drug conjugates, particularly the progress of its product ZYNLONTA. A live webcast of the session will be available for interested parties. ADC Therapeutics is actively involved in clinical and preclinical development for cancer treatments, indicating a robust pipeline for future growth.
Read more →ADCT▼ -9.2%on this newsshared move
ADC Therapeutics Announces $105 Million Underwritten Offering of Common Shares and Pre-Funded Warrants
ADC Therapeutics has announced a successful agreement for an underwritten offering of approximately $105 million, selling 13,411,912 common shares at $4.900 each. Additionally, they are offering pre-funded warrants to purchase 8,163,265 common shares. The proceeds from this offering are expected to aid in furthering their development of antibody drug conjugates targeting cancer. The transaction is set to close on May 8, 2024, pending customary closing conditions.
Read more →ADCT▼ -9.2%on this newsshared move
ADC Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
ADC Therapeutics reported its first quarter 2024 financial results, highlighting net sales of ZYNLONTA at $17.8 million, a 7% increase over the previous quarter but a 6% decrease year-over-year. The company successfully completed dose escalation in its LOTIS-7 clinical trial and initiated expansion in treating relapsed/refractory B-cell lymphoma. Encouraging initial Phase 2 data showed a high response rate in patients treated for marginal zone lymphoma. Overall, ADC Therapeutics outlined significant progress in its hematology strategy while advancing its portfolio of investigational ADC therapies.
Read more →ADCT▼ -9.2%on this newsshared move
ADC Therapeutics Announces Initial Data from Investigator-Initiated Phase 2 Clinical Trial of ZYNLONTA in Patients with Relapsed/Refractory Marginal Zone Lymphoma
ADC Therapeutics announced promising initial data from a Phase 2 clinical trial of ZYNLONTA in patients with relapsed/refractory marginal zone lymphoma. Out of 15 evaluable patients, 13 achieved a complete response, with all responses maintained at the data cutoff. The trial, led by the Sylvester Comprehensive Cancer Center, aims to evaluate the safety and efficacy of ZYNLONTA, which showed good tolerability. The company is optimistic about further expanding the trial to boost enrollment and address the unmet medical need in this rare lymphoma subtype.
Read more →ADCT▲ +6.8%on this newsshared move
ADC Therapeutics to Host First Quarter 2024 Financial Results and Pipeline Update Conference Call on May 6, 2024
ADC Therapeutics announced a conference call scheduled for May 6, 2024, to discuss its first quarter financial results and provide updates on its pipeline. The call will include insights into the company's progress with its proprietary antibody drug conjugates, particularly ZYNLONTA, which has received regulatory approvals. This update emphasizes the company's focus on maintaining transparency with its investors and stakeholders while navigating upcoming challenges in the industry.
Read more →ADCT▲ +6.3%on this news
ADC Therapeutics Announces Updates on LOTIS-7 Clinical Trial Evaluating ZYNLONTA in Combination with Glofitamab or Mosunetuzumab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
ADC Therapeutics announced the completion of dose escalation in the LOTIS-7 clinical trial, evaluating ZYNLONTA in combination with bispecific antibodies like glofitamab and mosunetuzumab for patients with relapsed/refractory B-cell non-Hodgkin lymphoma. The trial's Part 1 noted no dose-limiting toxicities, with early evidence of anti-tumor activity in most patients. Enrollment for Part 2 of the trial has begun, highlighting the therapeutic potential and favorable toxicity profile of this combination approach in heavily pre-treated cancer patients.
Read more →ADCTADC Therapeutics to Host a Virtual Research Investor Event on Tuesday, April 9, 2024
ADC Therapeutics has announced a virtual Research Investor Event scheduled for April 9, 2024, from 4:00 to 5:30 p.m. EDT. The event will include presentations by the CEO Ameet Mallik and CSO Patrick van Berkel, focusing on updates about the company's exatecan-based antibody drug conjugate platform. A live Q&A session will be available for attendees, and the company encourages preregistration to participate. This event reflects the company's ongoing commitment to engaging with investors and providing insights into its clinical advancements.
Read more →ADCT▼ -12.4%on this news
ADC Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
ADC Therapeutics reported its fourth quarter and full year 2023 financial results, highlighting net sales of $16.6 million in Q4, up 17% from Q3, despite a 16% year-over-year decline. The company noted a significant reduction in operating expenses due to strategic portfolio prioritization, with a cash position of $278.6 million extending the runway into Q4 2025. With ongoing clinical trials showing promising results, ADC Therapeutics is optimistic about its pipeline advancements and commercial viability in 2024.
Read more →ADCTADC Therapeutics to Host Fourth Quarter and Year-End 2023 Financial Results Conference Call on March 13, 2024
ADC Therapeutics has announced a conference call for March 13, 2024, to discuss its financial results for the fourth quarter and year-end 2023. The company continues to lead in the field of antibody drug conjugates, with its product ZYNLONTA having received regulatory approvals. The call will also provide business updates, reflecting ADC Therapeutics' commitment to transparency with its stakeholders. However, potential challenges related to competition and market acceptance of ZYNLONTA remain.
Read more →ADCTADC Therapeutics to Participate in the Guggenheim 5th Annual Healthy Altitudes Summit
ADC Therapeutics will participate in the Guggenheim 5th Annual Healthy Altitudes Summit, where CEO Ameet Mallik will give a fireside chat. This event will take place on March 12, 2024, and a live webcast will be available for investors. The company is recognized for its innovative antibody drug conjugates, particularly ZYNLONTA, which has received both FDA and European Commission approval for treating specific cancers. ADC continues to actively develop additional therapies and is rooted in Switzerland.
Read more →ADCTADC Therapeutics Business Overview Cowen Conference
ADC Therapeutics provided a business overview at the Cowen Conference, highlighting advancements in its drug pipeline, particularly with ZYNLONTA for treating diffuse large B-cell lymphoma (DLBCL) and the ongoing development of investigational antibody-drug conjugates (ADCs). The company reported a healthy cash position, which is expected to support operations into the fourth quarter of 2025. There are promising early results in clinical trials, although the discontinuation of ADCT-901 raises questions about resource allocation. Forward-looking statements regarding future revenue and strategic execution remain cautious.
Read more →ADCTADC Contract Manufacturing Market projected to reach USD 27.4 Billion by 2030, growing at a CAGR of 14.2% during the forecast period of 2023-2030 - a comprehensive study by MarketDigits
The ADC Contract Manufacturing market is expected to grow significantly, reaching USD 27.4 billion by 2030, driven by advancements in bioconjugation technologies and the rising demand for targeted cancer therapies. The forecast period from 2023 to 2030 predicts a compound annual growth rate (CAGR) of 14.2%. Key factors contributing to this growth include the increasing incidence of cancer, a focus on personalized medicine, and collaboration between pharmaceutical companies and contract manufacturing organizations. North America leads the market, with notable expansion also occurring in the Asia Pacific region.
Read more →ADCTADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cancer Research (AACR) Annual Meeting
ADC Therapeutics has announced that several of its abstracts related to novel antibody drug conjugates (ADCs) have been accepted for presentation at the AACR Annual Meeting in San Diego, CA, scheduled for April 5-10, 2024. Key topics will include preclinical developments of ADCs targeting Claudin-6 and NaPi2b. Additionally, there will be presentations on ADCT-601, which targets AXL, demonstrating various studies that support its development in cancer treatment.
Read more →ADCTADC Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
ADC Therapeutics announced that CEO Ameet Mallik will present an overview at the TD Cowen 44th Annual Health Care Conference on March 5, 2024. The event will provide a platform for the company to highlight its advancements in antibody drug conjugates, especially its FDA-approved product ZYNLONTA for certain lymphoma treatments. Investors can access a live webcast of this presentation on the company's website. The company aims to transform cancer treatment paradigms with its innovative therapies.
Read more →ADCT▲ +13.3%on this news· ran to +25% by day 3
ADC Therapeutics Regains Compliance with NYSE Continued Listing Standards
ADC Therapeutics announced that it has regained compliance with the NYSE's continued listing standards after a previous notice indicated a noncompliance issue. The company's common shares have returned to an average closing price above $1.00, thus removing them from the NYSE's noncompliant issuers list. This development is expected to positively impact investor sentiment and market standing for the company.
Read more →ADCT▲ +13.3%on this news· ran to +25% by day 3
ADC Therapeutics Provides Business Updates
ADC Therapeutics recently provided business updates highlighting a projected increase in net sales of Zynlonta for Q4 2023 to approximately $16.5 million. The company reported positive progress in clinical trials, particularly the LOTIS-7 trial, which showed early efficacy signals without significant safety issues. Additionally, ADCT-601 is in dose optimization and displaying early antitumor activity. However, the firm has discontinued the ADCT-901 program due to limited signs of efficacy and is focusing on its prioritized projects for future growth.
Read more →ADCT▲ +13.3%on this news· ran to +25% by day 3
ADC Therapeutics Provides Business Updates ZYNLONTA 1 4Q 2023 net sales expected to be ~$16.5 million, a double-digit percentage increase as compared to 3Q 2023 LOTIS-7: Study of ZYNLONTA in combination with bispecifics
ADC Therapeutics has announced positive business updates highlighting a projected quarterly net sales increase of approximately $16.5 million for ZYNLONTA. The company reported encouraging early signs of efficacy in the LOTIS-7 trial and reached the maximum tolerated dose (MTD) for ADCT-601, demonstrating antitumor activity. With a strengthened pipeline and organizational structure, ADC anticipates multiple data catalysts in 2024 and has extended its cash runway into Q4 2025. These updates are indicative of a potential commercial turnaround for the company.
Read more →ADCTADC Therapeutics Announces Initial Results from Investigator-Initiated Phase 2 Clinical Trial Evaluating ZYNLONTA in Combination with Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma (FL)
ADC Therapeutics announced encouraging initial results from a Phase 2 trial evaluating ZYNLONTA in combination with rituximab for patients with relapsed or refractory follicular lymphoma. Key findings include a 96% overall response rate and an 85% complete response rate among participants. Following a median follow-up of 9.7 months, the progression-free survival rate stands at 92.3%. Based on these results, the company plans to expand the trial into a multicenter study in early 2024 to further explore this treatment approach.
Read more →ADCT▼ -16%on this news· ran to -46% by day 3
ADC Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates 3Q 2023 ZYNLONTA 1 net sales of $14.3 million reflect disruption following restructuring of commercial organization, increased c
ADC Therapeutics reported a net sales decline for ZYNLONTA in Q3 2023, totaling $14.3 million, largely due to market competition and a restructuring of its commercial operations. Despite a drop in sales, the company has reduced operating expenses and expects to maintain a solid cash position into mid-2025. The pipeline for ZYNLONTA and other compounds is progressing, with several data readouts anticipated in the first half of 2024. Additional challenges include a larger net loss reported for the quarter compared to the previous year, attributed mainly to reduced revenue.
Read more →ADCT▼ -16%on this news· ran to -46% by day 3
ADC Therapeutics Receives NYSE Notice of Non-Compliance With Continued Listing Standards Lausanne, Switzerland
ADC Therapeutics received a notice from the NYSE on October 10, 2023, indicating non-compliance with the minimum share price requirement of $1.00. The company has a six-month period to regain compliance, during which its shares will remain listed. To address this issue, ADC may consider a reverse share split, pending approval from its board and shareholders. The notice does not have an immediate effect on trading, but the company must meet other continued listing requirements.
Read more →ADCT▲ +7.9%on this news· ran to -41% by day 3shared move
ADC Therapeutics to Participate in the Jefferies London Healthcare Conference
ADC Therapeutics announced that CEO Ameet Mallik will participate in a fireside chat at the Jefferies London Healthcare Conference on November 14, 2023. This event highlights the company’s ongoing efforts in the field of antibody drug conjugates. ADC Therapeutics is recognized for its innovative approach to treating hematologic malignancies with products like ZYNLONTA, which has received regulatory approvals. Investors can access a live webcast of the discussion on the company's website.
Read more →ADCTADC Therapeutics Announces Abstracts Accepted for Presentation at the 65th ASH Annual Meeting
ADC Therapeutics announced that abstracts regarding ZYNLONTA will be presented at the 65th ASH Annual Meeting, highlighting its clinical utility. The presentations will include promising data from an investigator-initiated Phase 2 study showing a 95% overall response rate when ZYNLONTA is combined with rituximab in patients with relapsed or refractory follicular lymphoma. The meeting is scheduled for December 9-12, 2023, in San Diego, California. This research supports ZYNLONTA's position as a valuable treatment for certain B-cell malignancies.
Read more →ADCTADC Therapeutics to Host Third Quarter 2023 Financial Results Conference Call on November 7, 2023
ADC Therapeutics announced a conference call scheduled for November 7, 2023, to discuss its financial results for the third quarter of 2023 and provide updates on its business. The company continues to grow in the field of antibody drug conjugates with ZYNLONTA receiving accelerated and conditional approvals. As a commercial-stage leader, ADC Therapeutics also has multiple ADCs under clinical and preclinical development. The call is expected to give further insights into the company's strategies and financial health.
Read more →ADCTMorgan Stanley Global Healthcare Conference
ADC Therapeutics presented at the Morgan Stanley Global Healthcare Conference, discussing its strategic plans and financial health. The company emphasized its focus on maximizing the commercial potential of ZYNLONTA and advancing its PBD-based pipeline with several clinical programs in development. Despite a strong cash position and recent international sales, ADC acknowledged ongoing risks related to dependence on regulatory approvals and the achievement of its financial targets. The company projects a cash runway into mid-2025 and aims to unlock greater value through its innovative strategies.
Read more →ADCT▼ -7.4%on this news
ADC Therapeutics to Participate in September Investor Conferences
ADC Therapeutics SA (NYSE: ADCT) announced that CEO Ameet Mallik will participate in two investor conferences in September 2023. The events include fireside chats at the Morgan Stanley and Cantor Global Healthcare Conferences, which aim to engage investors and present the company's developments. The live webcasts of these discussions will be accessible on the company's investor website, potentially increasing the visibility of ADC Therapeutics' advancements in the field.
Read more →ADCTADC Therapeutics Announces Updates on ZYNLONTA LOTIS Clinical Trial Programs at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023)
ADC Therapeutics announced promising updates regarding its ZYNLONTA clinical trial programs at the SOHO 2023 meeting. The LOTIS-5 Phase 3 trial demonstrated an 80% overall response rate and a 50% complete response rate for ZYNLONTA combined with rituximab, with no new safety concerns identified. Meanwhile, the LOTIS-7 trial is actively enrolling patients to evaluate ZYNLONTA in various bispecific combinations aimed at treating relapsed or refractory non-Hodgkin lymphoma. Both trials represent significant advancements in ADC Therapeutics’ development pipeline for hematologic malignancies.
Read more →ADCT▲ +11.9%on this news
ADC Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update 2Q 2023 ZYNLONTA 1 net sales increased 11% year-over-year Implemented new go-to-market strategy during the quarter to support gr
ADC Therapeutics reported its second-quarter 2023 financial results, highlighting an 11% year-over-year increase in ZYNLONTA net sales and the implementation of a new go-to-market strategy. The company achieved a significant milestone with its first European commercial sale of ZYNLONTA, triggering a $75 million payment. Financially, ADC Therapeutics reported a net loss reduction and maintains a cash runway until mid-2025. However, it faces challenges, including a partial clinical hold on one of its trials and higher gross-to-net deductions impacting revenues.
Read more →ADCTADC Therapeutics to Host Second Quarter 2023 Financial Results Conference Call on August 8, 2023
ADC Therapeutics announced it will host a conference call on August 8, 2023, to report its second quarter financial results and provide business updates. The company is recognized as a leader in antibody drug conjugates and has received accelerated approval for its product ZYNLONTA, aimed at treating relapsed or refractory diffuse large B-cell lymphoma. The press release includes forward-looking statements concerning potential risks that could impact financial performance and regulatory approvals.
Read more →ADCTADC Therapeutics Announces Plan to Discontinue the Phase 2 LOTIS-9 Clinical Trial of ZYNLONTA (loncastuximab tesirine-lpyl) and Rituximab in Unfit or Frail Previously Untreated DLBCL Patients
ADC Therapeutics announced it will discontinue the Phase 2 LOTIS-9 clinical trial for ZYNLONTA (loncastuximab tesirine-lpyl) in unfit or frail DLBCL patients. The decision comes after acknowledging difficulties in defining the target patient population and evaluating the treatment's benefit-risk profile. The FDA has issued a partial clinical hold on the trial, allowing existing patients to continue treatment if they are benefitting. The company plans to conclude the trial without further studies on this regimen in the specified patient demographics.
Read more →ADCTADC Therapeutics SA: Company Investigated by the Portnoy Law Firm
The Portnoy Law Firm has announced an investigation into ADC Therapeutics SA regarding potential securities violations. The firm is exploring whether the company and its officers have engaged in unlawful business practices. Investors who have lost money are encouraged to contact the firm for a complimentary case evaluation and to discuss their legal options. The investigation may lead to a class action lawsuit on behalf of affected investors.
Read more →ADCT▼ -21.9%on this news· ran to -36% by day 1shared move
ADC Therapeutics Announces Voluntary Pause of Enrollment in the Phase 2 LOTIS-9 Clinical Trial of ZYNLONTA (loncastuximab tesirine-lpyl) and Rituximab in Unfit or Frail Previously Untreated DLBCL Patients
ADC Therapeutics has announced a voluntary pause in the enrollment of new patients in the Phase 2 LOTIS-9 clinical trial for ZYNLONTA and rituximab, due to concerns regarding respiratory-related adverse events. A review indicated seven fatal events alongside additional grade 3 or 4 events among participants, all of whom had significant pre-existing health conditions. The company's decision allows for further investigation into the safety data and consultation with regulatory authorities. No additional trial data is expected to be reported by the end of the year.
Read more →ADCTADC Therapeutics Announces Evolution of Board of Directors
ADC Therapeutics announced the election of Robert W. Azelby to its Board of Directors, enhancing the board with his extensive biopharmaceutical experience. The new board will consist of nine directors, with a majority being independent. Four outgoing directors were acknowledged for their contributions to the company. The appointment is part of a strategic effort to leverage strengths in developing ADCs and advancing corporate goals.
Read more →ADCT▼ -5.8%on this newsshared move
Articles of Association of ADC Therapeutics SA (ADC Therapeutics AG) (ADC Therapeutics Ltd) Statuts de ADC Therapeutics SA (ADC Therapeutics AG) (ADC Therapeutics Ltd) Articles of Association of ADC Therapeutics SA Secti
ADC Therapeutics SA has outlined its Articles of Association, detailing the company's name, purpose, registered office, and share capital. The articles specify that the company is incorporated in Epalinges, Vaud, with a focus on biotechnology and related fields. Additionally, the share capital is set at CHF 7,123,355.68, divided into approximately 89 million registered shares. There are provisions for capital fluctuations and share issuance, which can impact the company's financial strategies.
Read more →ADCTADC Therapeutics Announces Updated LOTIS-2 Results Demonstrating Durable, Long-Term Responses of ZYNLONTA in Relapsed/Refractory DLBCL
ADC Therapeutics announced updated results from the LOTIS-2 trial for ZYNLONTA in treating relapsed/refractory diffuse large B-cell lymphoma. Key findings include a 48.3% overall response rate and a significant 31% of patients remaining event-free for over two years post-treatment. The data highlight ZYNLONTA's potential long-term efficacy and safety, which will be further discussed during presentations at upcoming medical conferences. No new safety concerns were raised, although some adverse events were noted among participants.
Read more →ADCTADC Therapeutics to Participate in the Jefferies Healthcare Conference
ADC Therapeutics (NYSE: ADCT) announced that CEO Ameet Mallik will participate in a fireside chat at the Jefferies Healthcare Conference on June 8, 2023. The event will be accessible through a live webcast on the company's website, and a replay will be available for 30 days thereafter. ADC Therapeutics is recognized for its lead product, ZYNLONTA, which received accelerated FDA approval for certain lymphoma treatments. The company continues to develop additional ADCs and is focused on transforming cancer treatment paradigms.
Read more →ADCTADC Therapeutics Reports First Quarter 2023 Financial Results and Provides Business and Strategy Update 1Q 2023 ZYNLONTA 1 net sales increased 15% and operating expenses decreased 19% year-over-year 2 FY 2023 guidance re
ADC Therapeutics reported its first quarter 2023 financial results, highlighting a 15% increase in net sales of ZYNLONTA and a 19% decrease in operating expenses compared to the previous year. The company reaffirmed its FY 2023 guidance for continued double-digit sales growth alongside a new go-to-market model aimed at enhancing growth in both academic and community settings. Areview of the pipeline indicates a focus on key clinical programs, with initial data readouts expected in the next 12-15 months. Additionally, a corporate strategy shift includes a 17% workforce reduction to reprioritize investments in advanced programs.
Read more →ADCTTo the shareholders of ADC Therapeutics SA Invitation to the Annual General Meeting Date and Time : Wednesday
ADC Therapeutics SA has invited shareholders to its Annual General Meeting scheduled for June 14, 2023, to discuss 2022 achievements and strategic objectives for 2023. The company emphasizes the growth potential of its anti-cancer drug ZYNLONTA, which received conditional approvals in Europe and the UK. Furthermore, ADC Therapeutics is committed to advancing its pipeline, including upcoming trials for additional ADC programs, while maintaining a strong financial position projected to last until mid-2025.
Read more →ADCT▼ -10.1%on this news
ADC Therapeutics SA Biop le Route de la Corniche 3B 1066 Epalinges Switzerland
ADC Therapeutics SA has entered into a Letter Agreement with A.T. Holdings II S rl regarding an underwritten public offering of at least 12 million common shares. The offering will be led by Jefferies LLC, with the Company cooperating in the registration and marketing of the shares. The Company is to file a prospectus supplement, ensuring compliance with the Securities Act, while also supporting the Shareholder in selling the shares. This agreement outlines the rights and obligations of both parties in relation to the offering.
Read more →ADCTAmeet Mallik, CEO
ADC Therapeutics presented its strategic plans and updates at the J.P. Morgan Healthcare Conference. The company emphasized its strong technology platform, focusing on PBD-based antibody-drug conjugates (ADCs) and highlighted its cash runway through mid-2025. Upcoming value-driving catalysts were discussed, particularly in relation to ZYNLONTA and other pipeline assets. Overall, ADC Therapeutics is positioned as a leader in the ADC field with multiple clinical-stage programs.
Read more →ADCTADC Therapeutics to Participate in the 41 st Annual J.P. Morgan Healthcare Conference
ADC Therapeutics announced its participation in the 41st Annual J.P. Morgan Healthcare Conference scheduled for January 11th in San Francisco. CEO Ameet Mallik will provide an overview of the company and its products, including the approved ADC ZYNLONTA for treating diffuse large B-cell lymphoma. The presentation will be accessible via the company's website, with a replay available for 30 days. This conference presents an opportunity for ADC Therapeutics to showcase its advancements and engage with potential investors and partners.
Read more →ADCT▼ -6.5%on this newsshared move
ADC Therapeutics Appoints Mohamed Zaki as Chief Medical Officer
ADC Therapeutics has appointed Dr. Mohamed Zaki as its Chief Medical Officer, effective January 3, 2023, succeeding Dr. Joseph Camardo. Dr. Zaki, an industry veteran with over 20 years in oncology and hematology, has previously held roles at AbbVie and Celgene. The company anticipates that Dr. Zaki will enhance the development of its antibody drug conjugates, further advancing treatment options for cancer patients worldwide.
Read more →ADCTADC Therapeutics and Sobi Announce European Commission Approval of ZYNLONTA (loncastuximab tesirine) for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma Approval triggers $50 million milestone payme
ADC Therapeutics and Sobi Announce European Commission Approval of ZYNLONTA (loncastuximab tesirine) for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma $50 million milestone payment to ADC Therapeutics LAUSANNE, Switzerland, December 21, 2022 - ADC The
Read more →ADCT▼ -6.5%on this newsshared move
ADC Therapeutics Appoints Jose Carmona as Chief Financial Officer
ADC Therapeutics Appoints Jose Carmona as Chief LAUSANNE, Switzerland, December 19, 2022 - ADC Therapeutics SA (NYSE: ADCT) today announced the appointment of Jose "Pepe" Carmona as Chief Financial Officer (CFO), effective December 19, 2022. He will serve on the Company's exe
Read more →ADCTADC Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates ZYNLONTA (loncastuximab tesirine-lpyl) net sales of $21.3 million in the third quarter of 2022 (+23% vs.2Q 2022) Cash runway exp
ADC Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates ZYNLONTA (loncastuximab tesirine-lpyl) net sales of $21.3 million in the third quarter of 2022 (+23% vs.2Q 2022) Cash runway expected into early 2025 Company to host conference call t
Read more →ADCT▲ +5.8%on this newsshared move
ADC Therapeutics Announces Abstracts Accepted for Presentation at the 64 th ASH Annual Meeting Multiple presentations will highlight the clinical utility of ZYNLONTA (loncastuximab tesirine-lpyl) in DLBCL and Cami (camid
Announces Abstracts Accepted for Presentation at the 64th ASH Annual Meeting Multiple presentations will highlight the clinical utility of ZYNLONTA (loncastuximab tesirine-lpyl) in DLBCL and Cami (camidanlumab tesirine) in Hodgkin lymphoma Lausanne, Switzerland, November 3,
Read more →ADCT▼ -6.6%on this newsshared move
IGM Biosciences and ADC Therapeutics Announce Clinical Collaboration Agreement to Evaluate Imvotamab (IGM-2323) in Combination with ZYNLONTA in Patients with Relapsed or Refractory B Cell Non-Hodgkin's Lymphoma - Compani
and ADC Therapeutics Announce Clinical Collaboration Agreement to Evaluate Imvotamab (IGM-2323) in Combination with ZYNLONTA in Patients with Relapsed or Refractory B Cell Non-Hodgkin's Lymphoma to Leverage Lead Product Candidate from IGM's Proprietary IgM Antibody Platform wit
Read more →ADCTADC Therapeutics to Host Third Quarter 2022 Financial Results Conference Call on
ADC Therapeutics to Host Third Quarter 2022 Financial Results Conference Call on November Lausanne, Switzerland, October 31, 2022 - ADC Therapeutics SA (NYSE: ADCT) today announced that it will host a conference call and live webcast on Tuesday, November 8, 2022 at 8:30 a.m.
Read more →ADCTADC Therapeutics SA Investors: Company Investigated by the Portnoy Law Firm
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Sept. 20, 2022 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises ADC Therapeutics SA (“ADC” or “the Company”) (NYSE: ADCT) investors that the firm has initiated an investigatio
Read more →ADCT▼ -6.2%on this news
ADC Therapeutics to Participate in Morgan Stanley's 20 th Annual Global Healthcare Conference
Therapeutics to Participate in Morgan Stanley's 20th Annual Global Healthcare Conference Switzerland, September 6, 2022 - ADC Therapeutics SA (NYSE: ADCT) announced today that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at Morgan Stanley's 20th An
Read more →ADCTADC Contract Manufacturing Market by Phase of Development, Scale of Operation, Type of Component Manufacturing, Target Indications, Type of Payload, Type of Linker, Type of Antibody Origin, Antibody Isotype and Geography, 2022-2035
New York, Aug. 24, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "ADC Contract Manufacturing Market by Phase of Development, Scale of Operation, Type of Component Manufacturing, Target Indications, Type of Payload, Type of Linker, Type of Antibody
Read more →ADCT▼ -9.9%on this news
WARRANT TO PURCHASE COMMON SHARES OF ADC THERAPEUTICS SA No. W-DF[_]
TO PURCHASE COMMON SHARES OF FOR VALUE RECEIVED, the undersigned, ADC Therapeutics SA, a Swiss stock corporation (soci t anonyme) organized under the laws of Switzerland (together with its successors and assigns, the "Company"), hereby certifies that or its registered assign
Read more →ADCTADC Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates ZYNLONTA (loncastuximab tesirine-lpyl) net sales of $17.3 million in the second quarter of 2022 Ex-U.S. ZYNLONTA license agreem
ADC Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates ZYNLONTA (loncastuximab tesirine-lpyl) net sales of $17.3 million in the second quarter of 2022 Ex-U.S. ZYNLONTA license agreement with Sobi facilitates global patient access and exte
Read more →ADCTADC Therapeutics to Host Second Quarter 2022 Financial Results Conference Call on
ADC Therapeutics to Host Second Quarter 2022 Financial Results Conference Call on August 9, Lausanne, Switzerland, August 2, 2022 - ADC Therapeutics SA (NYSE: ADCT) today announced that it will host a conference call and live webcast on Tuesday, August 9, 2022 at 8:30 a.m. ET
Read more →ADCT▼ -5.5%on this news
ADC Therapeutics Names David Gilman as Chief Business & Strategy Officer Seasoned life sciences executive brings extensive business development expertise
ADC Therapeutics Names David Gilman as Chief Business & Strategy Officer Seasoned life sciences executive brings extensive business development expertise LAUSANNE, Switzerland, June 13, 2022 - ADC Therapeutics SA (NYSE: ADCT) announced today it has appointed industry veteran
Read more →ADCTADC Therapeutics to Present at the Jefferies Healthcare Conference
ADC Therapeutics to Present at the Jefferies Healthcare Conference LAUSANNE, Switzerland, June 1, 2022 - ADC Therapeutics SA (NYSE: ADCT) announced today that its Chief Executive Officer, Ameet Mallik, will be participating in a fireside chat at the Jefferies Healthcare Confe
Read more →ADCTTo the shareholders of ADC Therapeutics SA Invitation to the Annual General Meeting Date and Time : Thursday
To the shareholders of ADC Invitation to the Annual General Meeting Date and Time: Thursday, June 30, 2022, at 7:30 a.m. EDT / 1:30 p.m. CEST Location: Headquarters of ADC Therapeutics SA, Biop le, Route de la Corniche 3B, 1066 Epalinges, Switzerland (no physical shareholder
Read more →ADCTADC Therapeutics Announces Abstracts to be Presented at the European Hematology Association 2022 Hybrid Congress Oral presentation of pivotal Phase 2 clinical trial of Cami in relapsed or refractory Hodgkin lymphoma ZYNL
ADC Therapeutics Announces Abstracts to be Presented at the European Hematology Association 2022 Hybrid Congress Oral presentation of pivotal Phase 2 clinical trial of Cami in relapsed or refractory Hodgkin lymphoma large B-cell lymphoma data highlighted in several abstracts
Read more →ADCT▼ -28.7%on this newsshared move
ADC Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Updates Co-Founder Chris Martin transitions CEO role to industry veteran Ameet Mallik ZYNLONTA (loncastuximab tesirine-lpyl) net sales o
ADC Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Updates Co-Founder Chris Martin transitions CEO role to industry veteran Ameet Mallik ZYNLONTA (loncastuximab tesirine-lpyl) net sales of $16.5 million in the first quarter of 2022 Company to
Read more →ADCT▼ -28.7%on this newsshared move
ADC Therapeutics Announces CEO Transition Co-Founder Chris Martin transitions CEO role to industry veteran Ameet Mallik Dr. Martin to serve on Board of Directors and as Chair of the Science and Technology Committee Lausa
ADC Therapeutics Announces CEO Transition Co-Founder Chris Martin transitions CEO role to industry veteran Ameet Mallik Dr. Martin to serve on Board of Directors and as Chair of the Science and Technology Committee Lausanne, Switzerland, May 9, 2022 - ADC Therapeutics SA (N
Read more →ADCTADC Therapeutics to Present at the BofA Securities 2022 Healthcare Conference
ADC Therapeutics to Present at the BofA Securities 2022 Healthcare Conference LAUSANNE, Switzerland, May 4, 2022 - ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted ant
Read more →ADCTADC Therapeutics to Host First Quarter 2022 Financial Results Conference Call on
ADC Therapeutics to Host First Quarter 2022 Financial Results Conference Call on May 9, 2022 Lausanne, Switzerland, May 3, 2022 - ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation
Read more →ADCT▲ +5.3%on this news
ADC Therapeutics Releases its Annual Report on Form 20-F for the Fiscal Year Ended
Releases its Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2021 LAUSANNE, Switzerland, March 17, 2022 - ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targ
Read more →ADCT▼ -8.9%on this news
ADC Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Updates ZYNLONTA (loncastuximab tesirine-lpyl) net sales of $17.0 million in the fourth quarter of 2021 and $33.9 million
ADC Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Updates ZYNLONTA (loncastuximab tesirine-lpyl) net sales of $17.0 million in the fourth quarter of 2021 and $33.9 million in FY 2021 following May launch LOTIS-5 Phase 3 confi
Read more →ADCTADC Therapeutics to Participate in Cowen's 42 nd Annual Health Care Conference
ADC Therapeutics to Participate in Cowen's 42nd Annual Health Care Conference LAUSANNE, Switzerland, March 1, 2022 - ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted a
Read more →ADCT▲ +5.5%on this newsshared move
ADC Therapeutics to Host Fourth Quarter and Year-End 2021 Financial Results Conference Call on
ADC Therapeutics to Host Fourth Quarter and Year-End Financial Results Conference Call on March 3, Lausanne, Switzerland, February 24, 2022 - ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its ne
Read more →ADCTADC Therapeutics Releases its Inaugural Environmental, Social and Governance Report Report documents ESG accomplishments and reflects commitment to corporate responsibility
ADC Therapeutics Releases its Inaugural Environmental, Social and Governance Report Report documents ESG accomplishments and reflects commitment to corporate responsibility LAUSANNE, Switzerland, February 17, 2022 - ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotec
Read more →ADCTADC Therapeutics to Participate in Guggenheim Oncology Conference
ADC Therapeutics to Participate in Guggenheim LAUSANNE, Switzerland, February 2, 2022 - ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs)
Read more →ADCTADC Cytotoxic Payloads / Warheads: Products and Services Market, 2021-2035
New York, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "ADC Cytotoxic Payloads / Warheads: Products and Services Market, 2021-2035" - https://www.reportlinker.com/p06225957/?utm_source=GNW Over time, medical researchers have been able to
Read more →ADCT▼ -6.5%on this news
ADC Therapeutics to Host Webcast Highlighting its ADC Platform and Solid Tumor Pipeline on
ADC Therapeutics to Host Webcast Highlighting and Solid Tumor Pipeline on February 8, 2022 LAUSANNE, Switzerland, January 20, 2022 - ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-genera
Read more →ADCTADC Therapeutics Announces Abstracts to be Presented at the 63 rd ASH Annual Meeting Several presentations will highlight broad potential of CD19-targeted ADC ZYNLONTA (loncastuximab tesirine-lpyl) as a single agent and
Announces Abstracts to be Presented at the 63rd ASH Annual Meeting Several presentations will highlight broad potential of CD19-targeted ADC ZYNLONTA (loncastuximab tesirine-lpyl) as a single agent and in combination for the treatment of non-Hodgkin lymphomas Lausanne, Switze
Read more →ADCT▼ -7.4%on this newsshared move
ADC Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Updates ZYNLONTA (loncastuximab tesirine-lpyl) third quarter 2021 net sales of $13.1 million Financing agreement with HealthCare Royalty
ADC Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Updates ZYNLONTA (loncastuximab tesirine-lpyl) third quarter 2021 net sales of $13.1 million Financing agreement with HealthCare Royalty for up to $325 million Company to host conference call t
Read more →ADCTADC Therapeutics to Host Third Quarter 2021 Financial Results Conference Call on
ADC Therapeutics to Host Third Quarter 2021 Financial Results Conference Call on November Lausanne, Switzerland, October 27, 2021 - ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generat
Read more →ADCTADC Therapeutics to Participate in the 2021 Cantor Virtual Global Healthcare Conference
to Participate in the 2021 Cantor Virtual Global Healthcare Conference LAUSANNE, Switzerland, September 23, 2021 - ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted anti
Read more →ADCTADC Therapeutics to Participate in Morgan Stanley's 19 th Annual Global Healthcare Conference
to Participate in Morgan Stanley's 19th Annual Global Healthcare Conference LAUSANNE, Switzerland, September 9, 2021 - ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted
Read more →ADCTCertain confidential information contained in this document, marked by [**], has been omitted because ADC Therapeutics SA (ADCT) has determined that the information (i) is not material and (ii) is the type that ADCT cust
Certain confidential information contained in this document, marked by [**], has been omitted because ADC Therapeutics SA (ADCT) has determined that the information (i) is not material and (ii) is the type that ADCT customarily and actually treats as private or confidential. b
Read more →ADCT▲ +8.9%on this news· ran to +24% by day 3
ADC Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Updates - Encouraging initial launch of ZYNLONTA (loncastuximab tesirine-lpyl) driven by favorable product profile to address high unme
ADC Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Updates -Encouraging initial launch of ZYNLONTA (loncastuximab tesirine-lpyl) driven by favorable product profile to address high unmet medical need in relapsed refractory DLBCL market -Company
Read more →ADCTADC Therapeutics to Host Second Quarter 2021 Financial Results Conference Call on
ADC Therapeutics to Host Second Quarter 2021 Financial Results Conference Call on August 3, Lausanne, Switzerland, July 28, 2021 - ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to tr
Read more →ADCTADC Therapeutics Announces Presentations at the 16 th Annual International Conference on Malignant Lymphoma Oral presentation of preliminary results from ongoing pivotal Phase 2 trial of camidanlumab tesirine in r/r Hodg
Announces Presentations at the 16th Annual International Conference on Malignant Lymphoma of preliminary results from ongoing pivotal Phase 2 trial of camidanlumab tesirine in r/r Hodgkin lymphoma LOTIS trials evaluating ZYNLONTATM as single agent and in combination with other
Read more →ADCTADC Therapeutics Presents Updated Clinical Data at 2021 ASCO Annual Meeting ZYNLONTA LOTIS-2 updated data includes median duration of response of 13.4 months in heavily pre-treated patients with relapsed or refractory DL
Presents Updated Clinical Data at 2021 ASCO Annual Meeting LOTIS-2 updated data includes median duration of response of 13.4 months in heavily pre-treated patients with relapsed or refractory include patients with double- / triple-hit, advanced stage or transformed DLBCL, DLBC
Read more →ADCTADC Therapeutics to Present at Jefferies Virtual Healthcare Conference
to Present at Jefferies Virtual Healthcare Conference LAUSANNE, Switzerland, May 27, 2021 - ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematological malignancies and solid
Read more →ADCTADC Therapeutics Announces Online Publication of Camidanlumab Tesirine Phase 1 Results in The Lancet Haematology Camidanlumab tesirine (Cami) demonstrated anti-tumoral activity response rate in 86% of Hodgkin lymphoma pa
ADC Therapeutics Announces Online Publication of Camidanlumab Tesirine Phase 1 Results in The Lancet Haematology Camidanlumab tesirine (Cami) demonstrated anti-tumoral activity response rate in 86% of Hodgkin lymphoma patients at dose currently being evaluated in ongoing pivo
Read more →ADCTADC Therapeutics Announces Presentations at the 2021 ASCO Annual Meeting Posters to highlight ZYNLONTA LOTIS-2 subgroup analyses, ZYNLONTA LOTIS-5 confirmatory trial and Cami in advanced solid tumors
ADC Therapeutics Announces Presentations at the 2021 ASCO Annual Meeting Posters to highlight ZYNLONTA LOTIS-2 subgroup analyses, ZYNLONTA LOTIS-5 confirmatory trial and Cami in advanced solid tumors LAUSANNE, Switzerland, May 19, 2021 - ADC Therapeutics SA (NYSE: ADCT), a c
Read more →ADCTTHE SECURITIES REPRESENTED BY THIS NOTE AND THE COMMON SHARES ISSUABLE UPON CONVERSION THEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE " SECURITIES ACT "), OR APPLICABLE STATE SECURITIE
REPRESENTED BY THIS NOTE AND THE COMMON SHARES ISSUABLE UPON CONVERSION THEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"), OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES REPRESENTED BY THIS NOTE AND THE COMMON SHARES ISSUA
Read more →ADCTADC Therapeutics Announces Receipt of $50 Million Second Tranche of Convertible Credit Facility with Deerfield
ADC Therapeutics Announces Receipt of $50 Million Second Tranche of Convertible Credit Facility with Deerfield LAUSANNE, Switzerland, May 17, 2021 - ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conju
Read more →ADCTADC Therapeutics Announces Online Publication of LOTIS-2 Results in The Lancet Oncology Recent FDA approval of ZYNLONTA (loncastuximab tesirine-lpyl) was based on data from LOTIS-2 ZYNLONTA TM demonstrated substantial si
Announces Online Publication of LOTIS-2 Results in of ZYNLONTA (loncastuximab tesirine-lpyl) was based on data from LOTIS-2 demonstrated substantial single-agent activity, durable responses and an acceptable safety profile in broad population of difficult-to-treat patients wit
Read more →ADCTADC Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Updates - ZYNLONTA (loncastuximab tesirine-lpyl) granted accelerated FDA approval for patients with relapsed or refractory diffuse large
ADC Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Updates -ZYNLONTA (loncastuximab tesirine-lpyl) granted accelerated FDA approval for patients with relapsed or refractory diffuse large B-cell lymphoma -Commercial launch progressing well order
Read more →ADCTADC Therapeutics' ZYNLONTA (loncastuximab tesirine-lpyl) Added to National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for B-cell Lymphomas - ZYNLONTA is the first and only CD19-targeted ADC app
ADC Therapeutics' ZYNLONTA (loncastuximab tesirine-lpyl) Added to National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for B-cell Lymphomas ZYNLONTA is the first and only CD19-targeted ADC approved as a single-agent treatment for adult patients with r/
Read more →ADCTADC Therapeutics to Participate in May Investor Conferences
ADC Therapeutics to Participate in May Investor LAUSANNE, Switzerland, May 4, 2021 - ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematological malignancies and solid tumors
Read more →ADCTADC Therapeutics to Host First Quarter 2021 Financial Results Conference Call on
ADC Therapeutics to Host First Quarter 2021 Financial Results Conference Call on May 6, 2021 Lausanne, Switzerland, April 29, 2021 - ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to t
Read more →ADCTADC Therapeutics Announces FDA Approval of ZYNLONTA (loncastuximab tesirine-lpyl) in Relapsed or Refractory Diffuse Large B-Cell Lymphoma First and only CD19-targeted antibody drug conjugate (ADC) as a single-agent treat
Announces FDA Approval of ZYNLONTA (loncastuximab tesirine-lpyl) in Relapsed or Refractory Diffuse Large B-Cell Lymphoma CD19-targeted antibody drug conjugate (ADC) as a single-agent treatment for adult patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (D
Read more →ADCTOverland ADCT BioPharma Appoints Eric Koo as Chief Executive Officer Senior pharmaceutical executive with deep oncology experience in Asia formerly of Takeda, MSD, Bayer and Pfizer BOSTON, SHANGHAI and
Overland ADCT BioPharma Appoints Eric Koo as Chief Executive Officer Senior pharmaceutical executive with deep oncology experience in Asia formerly of Takeda, MSD, BOSTON, SHANGHAI and LAUSANNE, Switzerland, April 6, 2021 - Overland ADCT BioPharma, a joint venture created by
Read more →ADCTADC Therapeutics Reports Fourth Quarter and Year-End 2020 Financial Results and Provides Business Updates - Lonca BLA accepted by FDA with priority review; PDUFA date
ADC Therapeutics Reports Fourth Quarter and Year-End 2020 Financial Results and Provides Business Updates Lausanne, Switzerland, March 18, 2021 - ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and comm
Read more →ADCTADC Therapeutics to Host Fourth Quarter and Year-End 2020 Financial Results Conference Call on
ADC Therapeutics to Host Fourth Quarter Financial Results Conference Call on March Lausanne, Switzerland, March 11, 2021 - ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly
Read more →ADCTADC Therapeutics to Participate in Cowen 41 st Annual Health Care Conference
to Participate in Cowen 41st Annual LAUSANNE, Switzerland, February 25, 2021 - ADC Therapeutics SA (NYSE:ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates
Read more →ADCTADC Therapeutics to Participate in Guggenheim Healthcare Talks 2021 Oncology Day
to Participate in Guggenheim Healthcare Talks 2021 Oncology Day LAUSANNE, Switzerland, February 5, 2021 - ADC Therapeutics SA (NYSE:ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targete
Read more →ADCTADC Therapeutics Completes Enrollment in Pivotal Phase 2 Clinical Trial of Camidanlumab Tesirine (Cami) in Relapsed or Refractory Hodgkin Lymphoma Interim results anticipated in the first half of 2021
Completes Enrollment in Pivotal Phase 2 Clinical Trial of Camidanlumab Tesirine (Cami) in Relapsed or Refractory Hodgkin Lymphoma results anticipated in the first half of 2021 LAUSANNE, Switzerland, February 4, 2021 - ADC Therapeutics SA (NYSE:ADCT), a late clinical-stage onco
Read more →ADCTADC Therapeutics Initiates Expanded Access Program for Loncastuximab Tesirine in the U.S. Lausanne, Switzerland
ADC Therapeutics Initiates Expanded Access Program for Loncastuximab Tesirine in the U.S. Lausanne, Switzerland, January 7, 2020 - ADC Therapeutics SA (NYSE:ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of
Read more →ADCTADC Therapeutics to Participate in SternIR Virtual Corporate Access Event Lausanne, Switzerland
to Participate in SternIR Virtual Corporate Access Event Lausanne, Switzerland, January 4, 2020 - ADC Therapeutics SA (NYSE:ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibo
Read more →ADCTADC Therapeutics and Overland Pharmaceuticals Announce Formation of Overland ADCT BioPharma to Develop and Commercialize Lonca and other ADCs for Hematologic and Solid Tumor Indications in Greater China and Singapore - H
and Overland Pharmaceuticals Announce Formation of Overland ADCT BioPharma to Develop and Commercialize Lonca and other ADCs for Hematologic and Solid Tumor Indications in Greater China and Singapore Overland Pharmaceuticals to initially contribute $50 million to fund operation
Read more →ADCTADC Contract Manufacturing Market, 2020-2030
New York, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "ADC Contract Manufacturing Market, 2020-2030" - https://www.reportlinker.com/p03290025/?utm_source=GNW Over time, clinical researchers have been able to further their understanding
Read more →ADCTADC Therapeutics Announces Updated Clinical Data on Lead Antibody Drug Conjugate Programs Loncastuximab Tesirine (Lonca) and Camidanlumab Tesirine (Cami) Presented at 62 nd American Society of Hematology Annual Meeting L
ADC Therapeutics Announces Updated Clinical Data on Lead Antibody Drug Conjugate Programs Loncastuximab Tesirine (Lonca) and Camidanlumab Tesirine (Cami) Presented at 62nd American Society of Hematology Annual Meeting Lonca LOTIS 2 subgroup data include updated median duratio
Read more →ADCTADC Therapeutics to Host Conference Call Highlighting Data from its Next-Generation Antibody Drug Conjugates Being Presented at the 62 nd American Society of Hematology Annual Meeting - Mehdi Hamadani, MD, Medical Colleg
ADC Therapeutics to Host Conference Call Highlighting Data from its Next-Generation Antibody Drug Conjugates Being Presented at the 62nd American Society of Hematology Annual Meeting Lausanne, Switzerland, November 30, 2020 - ADC Therapeutics SA (NYSE:ADCT), a late clinical-s
Read more →ADCTADC Therapeutics Announces FDA Accepts Biologics License Application and Grants Priority Review for Loncastuximab Tesirine for Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma Prescription Drug User Fee
ADC Therapeutics Announces FDA Accepts Biologics License Application and Grants Priority Review for Loncastuximab Tesirine for Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma Drug User Fee Act target action date of May 21, 2021 Lausanne, Switzerland, Novembe
Read more →ADCTUnaudited IFRS Condensed Consolidated Interim Financial Statements as of and for the three and nine months ended
Unaudited IFRS Condensed Consolidated Interim Financial Statements as of and for the three and nine months ended September 30, 2020 Condensed Consolidated Interim Statement of Operations 2 Condensed Consolidated Interim Statement of Comprehensive Loss 3 Condensed Consolidated I
Read more →ADCTADC Therapeutics to Present at the Stifel 2020 Virtual Healthcare Conference Lausanne, Switzerland
ADC Therapeutics to Present at the Stifel 2020 Virtual Healthcare Conference Lausanne, Switzerland, November 10, 2020 - ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly po
Read more →ADCTADC Therapeutics to Host Third Quarter 2020 Financial Results Conference Call on
Therapeutics to Host Third Quarter 2020 Results Conference Call on November 12, 2020 Switzerland, November 5, 2020 - ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent
Read more →ADCTADC Therapeutics Announces Eight Presentations on Data from its Next-Generation Antibody Drug Conjugates at the 62 nd American Society of Hematology Annual Meeting Several presentations highlight lead candidate loncastux
Therapeutics Announces Eight Presentations on Data from its Next-Generation Antibody Drug Conjugates at the 62nd American Society of Hematology Annual Meeting presentations highlight lead candidate loncastuximab tesirine (Lonca); BLA under FDA review for the treatment of relaps
Read more →ADCTADC Therapeutics Announces First Patient Dosed with Camidanlumab Tesirine (Cami) in Combination with Pembrolizumab in Ongoing Phase 1b Clinical Trial in Selected Solid Tumors Lausanne, Switzerland
Therapeutics Announces First Patient Dosed with Camidanlumab Tesirine (Cami) in Combination with Pembrolizumab in Ongoing Phase 1b Clinical Trial in Selected Solid Tumors Lausanne, Switzerland, November 3, 2020 - ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology
Read more →ADCTGenmab and ADC Therapeutics Announce Amended Agreement for Camidanlumab Tesirine (Cami) Media Release Copenhagen, Denmark and Lausanne, Switzerland
Copenhagen, Denmark and Lausanne, Switzerland, October 30, Genmab A/S (Nasdaq: GMAB) and ADC Therapeutics SA (NYSE: ADCT) today announced that they have executed an amended agreement for ADC Therapeutics to continue the development and commercialization of camidanlumab tesirin
Read more →ADCTADC Therapeutics Announces Full Exercise of Underwriters' Option to Purchase Additional Common Shares Lausanne, Switzerland
ADC Therapeutics Announces Full Exercise of Underwriters' Option to Purchase Additional Common Shares Lausanne, Switzerland - October 9, 2020 - ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commerc
Read more →ADCTADC Therapeutics Announces Pricing of Public Offering Lausanne, Switzerland
ADC Therapeutics Announces Pricing of Lausanne, Switzerland - September 23, 2020 - ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjug
Read more →ADCTADC Therapeutics Announces Proposed Public Offering Lausanne, Switzerland
ADC Therapeutics Announces Proposed Public Lausanne, Switzerland - September 21, 2020 - ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug c
Read more →ADCTEX-1 2 dp137015_ex9901.htm ADC Therapeutics Submits Biologics License Application to the U.S. Food and Drug Administration for Loncastuximab Tesirine for Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma
Therapeutics Submits Biologics License Application to the U.S. Food and Drug Administration for Loncastuximab Tesirine for Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma based on efficacy and safety data from LOTIS 2 clinical trial Lausanne, Switzerland, Sep
Read more →ADCTADC Therapeutics Announces Presentation of Preliminary Findings from Phase 1b Clinical Trial of Camidanlumab Tesirine (Cami) in Advanced Solid Tumors at ESMO Virtual Congress 2020 P reliminary pharmacokinetic and biomark
Therapeutics Announces Presentation of Preliminary Findings from Phase 1b Clinical Trial of Camidanlumab Tesirine (Cami) in Advanced Solid Tumors at ESMO Virtual Congress 2020 pharmacokinetic and biomarker data support continued evaluation of Cami as a novel immuno-oncology app
Read more →ADCTADC Therapeutics Announces Publication Highlighting the Potential of Camidanlumab Tesirine (Cami) as a Novel Immuno-oncology Approach for Solid Tumor Cancers Preclinical study published in the Journal for ImmunoTherapy o
Announces Publication Highlighting the Potential of Camidanlumab Tesirine (Cami) as a Novel Immuno-oncology Approach for Solid study published in the Journal for ImmunoTherapy of Cancer supports continued evaluation of CD25-targeted ADC in Phase 1b clinical trial in selected ad
Read more →ADCTADC Therapeutics Gives Notice of Partial Waiver of Restrictions Pursuant to FINRA Rule 5131 Lausanne, Switzerland
Therapeutics Gives Notice of Partial Waiver of Restrictions Lausanne, Switzerland, September 4, 2020 - ADC Therapeutics SA (NYSE: ADCT), today gave notice that Morgan Stanley & Co. LLC and BofA Securities, Inc., the lead book-running managers in the Company's recent initial p
Read more →ADCTUnaudited IFRS Condensed Consolidated Interim Financial Statements as of and for the three and six months ended
Unaudited IFRS Condensed Consolidated Interim Financial Statements as of and for the three and six months ended June 30, 2020 Condensed Consolidated Interim Statement of Income 2 Condensed Consolidated Interim Statement of Comprehensive Income 3 Condensed Consolidated Interim B
Read more →ADCTADC Therapeutics to Report Second Quarter 2020 Financial Results on
ADC Therapeutics to Report Second Quarter Financial Results on August 18, 2020 Lausanne, Switzerland, August 12, 2020 - ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly po
Read more →ADCTADC Therapeutics Announces First Patient Dosed in Pivotal Phase 2 Portion of LOTIS 3 Clinical Trial of Loncastuximab Tesirine (Lonca) in Combination With Ibrutinib Combination is being evaluated in patients with relapsed
ADC Therapeutics Announces First Patient Dosed in Pivotal Phase 2 Portion of LOTIS 3 Clinical Trial of Loncastuximab Tesirine (Lonca) in Combination With Ibrutinib Combination is being evaluated in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) or
Read more →ADCTADC Therapeutics Announces U.S. Food and Drug Administration Has Lifted Partial Clinical Hold on Pivotal Phase 2 Clinical Trial of Camidanlumab Tesirine Lausanne, Switzerland
ADC Therapeutics Announces U.S. Food and Drug Administration Has Lifted Partial Clinical Hold on Pivotal Phase 2 Clinical Trial of Camidanlumab Tesirine Lausanne, Switzerland - July 6, 2020 - ADC Therapeutics SA (NYSE:ADCT), a clinical-stage oncology-focused biotechnology comp
Read more →ADCTADC Therapeutics Announces Maturing Data from Pivotal Phase 2 Clinical Trial and Phase 1/2 Combination Clinical Trial of Loncastuximab Tesirine (Lonca) in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphom
ADC Therapeutics Announces Maturing Data from Pivotal Phase 2 Clinical Trial and Phase 1/2 Combination Clinical Trial of Loncastuximab Tesirine (Lonca) in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma Lonca demonstrated an overall response rate of 48.3% a
Read more →ADCTADC Therapeutics Announces Pricing of Upsized Initial Public Offering
LAUSANNE, Switzerland, May 14, 2020 (GLOBE NEWSWIRE) -- ADC Therapeutics SA, a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates for patients suffering from hematologi
Read more →ADCTADC Therapeutics Announces Launch of Initial Public Offering
LAUSANNE, Switzerland, May 11, 2020 (GLOBE NEWSWIRE) -- ADC Therapeutics SA, a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates for patients suffering from hematologi
Read more →ADCTADC Therapeutics Announces a $115 Million Convertible Credit Facility with Deerfield
LAUSANNE, Switzerland, May 01, 2020 (GLOBE NEWSWIRE) -- ADC Therapeutics SA, a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent antibody drug conjugates (ADCs) for patients suffering from hematological ma
Read more →ADCTADC Therapeutics Appoints Victor Sandor, M.D., to Its Board of Directors
LAUSANNE, Switzerland, April 27, 2020 (GLOBE NEWSWIRE) -- ADC Therapeutics SA, a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent antibody drug conjugates (ADCs) for patients suffering from hematological
Read more →ADCTADC Therapeutics Files Registration Statement for Proposed Initial Public Offering
LAUSANNE, Switzerland, April 24, 2020 (GLOBE NEWSWIRE) -- ADC Therapeutics SA, a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates for patients suffering from hematolo
Read more →ADCTADC Therapeutics Appoints Jennifer Creel as Chief Financial Officer
LAUSANNE, Switzerland, April 21, 2020 (GLOBE NEWSWIRE) -- ADC Therapeutics SA, a clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent antibody drug conjugates (ADCs) for patients suffering from hematological malig
Read more →ADCTADC Therapeutics to Appoint Ron Squarer as Chairman of Its Board of Directors and an Advisor to the Company
LAUSANNE, Switzerland, March 19, 2020 (GLOBE NEWSWIRE) -- ADC Therapeutics SA, a clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent antibody drug conjugates (ADCs) for patients suffering from hematological malig
Read more →ADCTADC Therapeutics Appoints Joseph Camardo, MD, as Head of Medical Affairs
Former Celgene and Wyeth leader with 30 years of global biopharmaceutical experience joins company as it prepares for first Biologics License Application (BLA) submission LAUSANNE, Switzerland, Jan. 10, 2020 (GLOBE NEWSWIRE) -- ADC Therapeutics SA, a clinical-stage oncology-focu
Read more →ADCTADC Therapeutics Announces Positive Results from Pivotal Phase 2 Clinical Trial of Single Agent Loncastuximab Tesirine (ADCT-402) in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Exceeded primary endpoint target with 45.5% overall response rate, including 20% complete response rate, in 145-patient trial On track for Biologics License Application (BLA) submission in 3Q 2020 LAUSANNE, Switzerland, Jan. 09, 2020 (GLOBE NEWSWIRE) -- ADC Therapeutics SA, a c
Read more →ADCTADC Therapeutics Announces Oral Presentation of Interim Efficacy Data from Pivotal Phase 2 Clinical Trial of ADCT-402 (Loncastuximab Tesirine) in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma at 61st ASH Annual Meeting
Data on 52 patients in the 145-patient clinical trial highlight ADCT-402 (loncastuximab tesirine) continues to demonstrate anti-tumor activity and manageable toxicity in heavily pretreated patients Biologics License Application submission planned for 2H 2020 LAUSANNE, Switzerla
Read more →ADCTADC Therapeutics Announces Presentations at 61st American Society of Hematology (ASH) Annual Meeting
Presentations highlight lead product candidate ADCT-402 as a single agent and in combination with checkpoint inhibitor durvalumab for relapsed or refractory B-cell non-Hodgkin lymphomas Updated interim data from pivotal Phase 2 clinical trial of ADCT-402 selected for oral presen
Read more →ADCTADC Therapeutics Appoints Jennifer Herron as Chief Commercial Officer
LAUSANNE, Switzerland, Nov. 05, 2019 (GLOBE NEWSWIRE) -- ADC Therapeutics SA, a clinical-stage oncology-focused biotechnology company pioneering the development of highly potent antibody drug conjugates (ADCs) for patients suffering from hematological malignancies and solid tumor
Read more →ADCTADC Therapeutics Announces Publication of ADCT-402 Data in Clinical Cancer Research
LAUSANNE, Switzerland, Nov. 04, 2019 (GLOBE NEWSWIRE) -- ADC Therapeutics SA, a clinical-stage oncology-focused biotechnology company pioneering the development of highly potent and targeted antibody drug conjugates (ADCs) for patients suffering from hematological malignancies an
Read more →ADCTADC Therapeutics Doses First Patients in Pivotal Phase 2 Clinical Trial of ADCT-301 in Patients with Relapsed or Refractory Hodgkin Lymphoma
LAUSANNE, Switzerland, Oct. 17, 2019 (GLOBE NEWSWIRE) -- ADC Therapeutics SA, a clinical-stage oncology-focused biotechnology company pioneering the development of highly potent and targeted antibody drug conjugates (ADCs) for patients suffering from hematological malignancies an
Read more →ADCTADC Therapeutics Announces Withdrawal of Registration Statement
LAUSANNE, Switzerland, Oct. 02, 2019 (GLOBE NEWSWIRE) -- ADC Therapeutics SA, a clinical-stage oncology-focused biotechnology company pioneering the development of highly potent and targeted antibody drug conjugates (ADCs) for patients suffering from hematological malignancies an
Read more →ADCTADC Therapeutics and Freenome Enter Biomarker Development Collaboration
LAUSANNE, Switzerland and SOUTH SAN FRANCISCO, Calif., Aug. 26, 2019 (GLOBE NEWSWIRE) -- DC Therapeutics, an oncology drug discovery and development company that specializes in the development of antibody drug conjugates (ADCs), and Freenome, a biotechnology company that has pion
Read more →ADCTADC Therapeutics and SOPHiA GENETICS Partner for Biomarker Discovery in Pivotal Phase II Clinical Trial
LAUSANNE, Switzerland, Aug. 06, 2019 (GLOBE NEWSWIRE) -- ADC Therapeutics, an oncology drug discovery and development company that specializes in the development of antibody drug conjugates (ADCs), and SOPHiA GENETICS, a leader in Data-Driven Medicine, today announced they have e
Read more →ADCTADC Therapeutics Announces Final Close of Series E Financing Expansion
LAUSANNE, Switzerland, July 09, 2019 (GLOBE NEWSWIRE) -- ADC Therapeutics, an oncology drug discovery and development company that specializes in the development of antibody drug conjugates (ADCs), today announced the final close of a $103 million Series E financing expansion, br
Read more →ADCTADC Therapeutics Presents Clinical Data on ADCT-402 and ADCT-301 in Subtypes of Relapsed or Refractory Lymphoma at the 15th International Conference on Malignant Lymphoma
Ongoing pivotal Phase II clinical trial of ADCT-402 in patients with relapsed or refractory diffuse large B-cell lymphoma anticipated to complete enrollment in third quarter of 2019 Pivotal Phase II clinical trial of ADCT-301 in relapsed or refractory Hodgkin lymphoma expected t
Read more →ADCTADC Therapeutics Announces Presentations at the 15th International Conference on Malignant Lymphoma
Three oral presentations and one poster presentation Pyrrolobenzodiazepine-based antibody drug conjugates demonstrate potential for the treatment of relapsed or refractory lymphomas as single agents and in combination therapies LAUSANNE, Switzerland, June 12, 2019 (GLOBE NEWSWI
Read more →ADCTADC Therapeutics Announces Completion of a Series E Financing Expansion
LAUSANNE, Switzerland, June 12, 2019 (GLOBE NEWSWIRE) -- ADC Therapeutics, an oncology drug discovery and development company that specializes in the development of antibody drug conjugates (ADCs), today announced that it has closed a $76 million expansion of its Series E financi
Read more →ADCTADC Therapeutics and Adagene Announce License Agreement
ADC Therapeutics to develop next-generation masked antibody drug conjugates (ADCs), incorporating Adagene’s SAFEbody™ technology, with potential utility across multiple tumor types Collaboration enables focus on targets in which healthy tissue expression precludes development of
Read more →ADCTADC Therapeutics Announces First Patient Dosed in Phase I Clinical Trial of ADCT-402 (loncastuximab tesirine) and Ibrutinib in Patients with Advanced Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma
LAUSANNE, Switzerland, Feb. 20, 2019 (GLOBE NEWSWIRE) -- ADC Therapeutics, an oncology drug discovery and development company that specializes in the development of proprietary antibody drug conjugates (ADCs), today announced that the first patient has been dosed in a Phase I cli
Read more →ADCTADC Therapeutics Announces First Patient Dosed in Phase I Clinical Trial of ADCT-402 (loncastuximab tesirine) and IMFINZI (durvalumab) in Multiple Types of Advanced Non-Hodgkin Lymphoma
LAUSANNE, Switzerland, Feb. 13, 2019 (GLOBE NEWSWIRE) -- ADC Therapeutics, an oncology drug discovery and development company that specializes in the development of proprietary antibody drug conjugates (ADCs), today announced that the first patient has been dosed in a Phase I cli
Read more →ADCTADC Therapeutics Announces First Patient Dosed in Phase I Clinical Trial of ADCT-601 in Advanced Solid Tumors
LAUSANNE, Switzerland, Jan. 16, 2019 (GLOBE NEWSWIRE) -- ADC Therapeutics, an oncology drug discovery and development company that specializes in the development of proprietary antibody drug conjugates (ADCs), today announced that the first patient has been dosed in its Phase I c
Read more →ADCTADC Therapeutics Doses First Patient in Phase Ib Clinical Trial of ADCT-301 in Patients with Advanced Solid Tumors
LAUSANNE, Switzerland, Jan. 04, 2019 (GLOBE NEWSWIRE) -- ADC Therapeutics, an oncology drug discovery and development company that specializes in the development of proprietary antibody drug conjugates (ADCs), today announced that the first patient has been dosed in its Phase Ib
Read more →ADCTADC Therapeutics to Appoint Peter Hug, Ph.D., to Board of Directors
LAUSANNE, Switzerland, Jan. 03, 2019 (GLOBE NEWSWIRE) -- ADC Therapeutics, an oncology drug discovery and development company that specializes in the development of proprietary antibody drug conjugates (ADCs), today announced that Peter Hug, Ph.D., will be appointed to its board
Read more →ADCTADC Therapeutics Presents Updated Data from Clinical Trials of Novel Antibody Drug Conjugates
ADCT-402 (loncastuximab tesirine) continues to demonstrate acceptable safety profile and anti-tumor activity in patients with relapsed or refractory diffuse large B-cell lymphoma; data from 183-patient study supports continued evaluation in ongoing pivotal Phase II trial ADCT-30
Read more →ADCTADC Therapeutics Announces First Patients Dosed in Phase I/II Clinical Trial of ADCT-602 in Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
LAUSANNE, Switzerland, Nov. 27, 2018 (GLOBE NEWSWIRE) -- ADC Therapeutics, an oncology drug discovery and development company that specializes in the development of proprietary antibody drug conjugates (ADCs), today announced that the first patients have been dosed in a Phase I/I
Read more →ADCTADC Therapeutics Announces Presentations at 60th American Society of Hematology (ASH) Annual Meeting
New clinical data highlight potential of novel pyrrolobenzodiazepine-based antibody drug conjugates for the treatment of relapsed or refractory lymphomas LAUSANNE, Switzerland, Nov. 14, 2018 (GLOBE NEWSWIRE) -- ADC Therapeutics, an oncology drug discovery and development company
Read more →ADCTADC Therapeutics Announces Presentations at the Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting
Potential new immune-oncology therapy uses antibody drug conjugate (ADC) that targets regulatory T cells (Tregs) Highly potent anti-tumor activity of CD25-targeted ADC demonstrated in preclinical solid tumor models both as monotherapy and in combination with a PD-1 inhibitor Co
Read more →ADCTADC Therapeutics Doses First Patient in Pivotal Clinical Trial of ADCT-402 in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Phase II trial evaluating efficacy and safety of CD19-targeting antibody drug conjugate intended to support submission of Biologics License Application Top-line data expected in third quarter of 2019 LAUSANNE, Switzerland, Aug. 07, 2018 (GLOBE NEWSWIRE) -- ADC Therapeutics, an
Read more →ADCTADC Therapeutics Licenses Proprietary Antibodies From Five Prime Therapeutics, Adds an Additional Proprietary ADC Development Program in Oncology
LAUSANNE, Switzerland and SOUTH SAN FRANCISCO, Calif., Nov. 5, 2013 (GLOBE NEWSWIRE) -- ADC Therapeutics Sarl ('ADC Therapeutics'), a portfolio company of Auven Therapeutics and the oncology drug development company specializing in proprietary antibody drug conjugates ('ADCs'), a
Read more →Competitive Position
How ADCT ranks across every disease it competes inCompetitive Position is a premium feature
See how ADCT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial